Page last updated: 2024-12-08

griseofulvin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Griseofulvin: An antifungal agent used in the treatment of TINEA infections. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

griseofulvin : An oxaspiro compound produced by Penicillium griseofulvum. It is used by mouth as an antifungal drug for infections involving the scalp, hair, nails and skin that do not respond to topical treatment. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID441140
CHEMBL ID562
CHEBI ID27779
SCHEMBL ID21988
MeSH IDM0009641

Synonyms (263)

Synonym
BIDD:GT0024
MLS002152905
MLS002154239
(2s,6'r)-7-chloro-2',4,6-trimethoxy-6'-methyl-3h-spiro[1-benzofuran-2,1'-cyclohexan]-2'-ene-3,4'-dione
BRD-K08273968-001-05-9
grisovin
nsc-34533
fulcin
KBIO1_001376
DIVK1C_000154
KBIO1_000154
DIVK1C_006432
SDCCGMLS-0066450.P001
(2s,6'r)-7-chloro-2',4,6-trimethoxy-6'-methyl-3h,4'h-spiro[1-benzofuran-2,1'-cyclohex[2]ene]-3,4'-dione
fulvidex (veterinary)
griseofulvin (jan/usp/inn)
gre ,
D00209
gris-peg (tn)
grisactin v (tn)
SPECTRUM_000816
BSPBIO_000271
PRESTWICK_247
7-chloro-2',4,6-trimethoxy-6'-methylspiro[benzofuran-2(3h),1',- [2]cyclohexene]-3,4'-dione
(2s,5'r)-7-chloro-3',4,6-trimethoxy-5'-methyl-spiro[benzofuran-2,4'-cyclohex-2-ene]-1',3-dione
IDI1_000154
MEGXM0_000184
BSPBIO_001621
ACON0_000953
SPECTRUM5_000648
BPBIO1_000299
NCGC00091120-01
BIM-0051396.0001
gresfeed
spiro(benzofuran-2(3h),1'-(2)cyclohexene)-3,4'-dione, 7-chloro-2',4,6-trimethoxy-6'-methyl-, (1's-trans)-
fulvinil
spirofulvin
poncyl
griseofulvin forte
fulvicin bolus (veterinary)
neo-fulcin
ultragris-330
fulvicin-p/g
7-chloro-4,6,2'-trimethoxy-6'-methylgris-2'-en-3,4'-dione
biogrisin-fp
epa pesticide chemical code 471400
greosin
grifulin
delmofulvina
(2s,6'r)-7-chloro-2',4,6-trimethoxy-6'-methylbenzofuran-2-spiro-1'-cyclohex-2'-ene-3,4'-dione
grisactin ultra
curling factor
fulvicin-u/f (veterinary)
grifulvin
fulvina
(2s-trans)-7-chloro-2',4,6-trimethoxy-6'-methylspiro(benzofuran-2(3h),1'-(2)cyclohexene)-3,4'-dione
grisefuline
nsc 34533
ai3-51015
ultragris-165
caswell no. 471b
grisactin
7-chloro-2',4,6-trimethoxy-6'beta-methylspiro(benzofuran-2(3h),1'-(2)cyclohexene)-3,4'-dione
fulvican grisactin
einecs 204-767-4
murfulvin
griseomix
fulvistatin
usaf sc-2
griseofulvinum
guservin
griseofulvin, ultramicrocrystalline
griseofulvine [inn-french]
hsdb 1722
fulcine
fulvicin p/g 330
lamoryl
griseofulvina [inn-spanish]
likuden
griseofulvinum [inn-latin]
grysio
fulvicin p/g 165
fulvicin p/g
ccris 320
grizeofulvin
griseofulvin-forte
fungivin
grisofulvin
7-chloro-4,6-dimethoxycoumaran-3-one-2-spiro-1'-(2'-methoxy-6'-methylcyclohex-2'-en-4'-one)
griscofulvin
spiro(benzofuran-2(3h),1'-(2)cyclohexene)-3,4'-dione, 7-chloro-2',4,6-trimethoxy-6'-methyl-, (2s-trans)-
brn 0095226
126-07-8
griseofulvin
C06686
griseofulvin, from penicillium griseofulvum, 97.0-102.0%
griseofulvin, microcrystalline
DB00400
amudane
griseofulvin, ultramicrosize
NCGC00091120-03
NCGC00091120-02
KBIO2_001296
KBIOGR_001454
KBIO3_001121
KBIO2_006432
KBIO2_003864
KBIOSS_001296
SPECTRUM2_000213
SPECTRUM3_000161
SPECTRUM4_000927
SPBIO_000225
SPECPLUS_000336
NINDS_000154
SPECTRUM200046
PRESTWICK3_000226
ACON1_001843
MLS001304062
NCGC00091120-06
NCGC00091120-07
smr000718755
NCGC00091120-04
NCGC00091120-05
CHEBI:27779 ,
griseofulvina
griseofulvine
LMPK13060001
bdbm31775
griseofulvin and alpha-ifn
HMS2091A03
nsc-755822
griseofulvin,microsize
griseofulvin permeability diameter
griseofulvin, microsize
CHEMBL562
griseofulvin microsize
grisactin v
HMS500H16
(2s,5'r)-7-chloro-3',4,6-trimethoxy-5'-methylspiro[1-benzofuran-2,4'-cyclohex-2-ene]-1',3-dione
HMS1923E09
cpd000718755
NCGC00091120-09
NCGC00091120-08
HMS2095N13
HMS3259D05
G0384
(1's-trans)- 7-chloro-2',4,6-trimethoxy-6'-methylspiro(benzofuran-2(3h),1'-cyclohex-2'-ene)-3,4'-dione
(1's,6'r)-7-chloro-2',4,6-trimethoxy-6'-methylspiro(benzofuran-2(3h),1'-(2)cyclohexene)-3,4'-dione
32hrv3e3d5 ,
spiro(benzofuran-2(3h),1'-(2)cyclohexene)-3,4'-dione, 7-chloro-2',4,6-trimethoxy-6'-methyl-, (1's,6'r)-
5-18-05-00150 (beilstein handbook reference)
xuanjing
fulvicin-u/f powder and tablets
griseofulvin [usp:inn]
unii-32hrv3e3d5
fulvidex
griseofulvin [usp:inn:ban:jan]
EN300-52615
NCGC00256353-01
dtxcid20674
tox21_303005
dtxsid8020674 ,
tox21_202235
NCGC00259784-01
nsc755822
pharmakon1600-00200046
tox21_111087
HMS2235F13
S4071
CCG-38416
AKOS015896380
griseofulvin [ep monograph]
griseofulvin [mart.]
griseofulvin [vandf]
griseofulvin [jan]
griseofulvin [inn]
griseofulvin [hsdb]
griseofulvin [usp monograph]
griseofulvin [who-ip]
7-chloro-2',4,6-trimethoxy-6'.beta.-methylspiro(benzofuran-2(3h),1'-(2)cyclohexene)-3,4'-dione
griseofulvinum [who-ip latin]
griseofulvin [who-dd]
griseofulvin [green book]
griseofulvin [orange book]
griseofulvin permeability diameter [usp-rs]
griseofulvin [usp-rs]
griseofulvin [iarc]
griseofulvin [mi]
NC00616
DDUHZTYCFQRHIY-RBHXEPJQSA-N
SCHEMBL21988
tox21_111087_1
NCGC00091120-13
CS-3426
fulvicin uf
griseofulvin, antibiotic for culture media use only
Q-201178
HY-17583
AB00052005_07
mfcd00082343
griseofulvin powder
sr-01000837512
SR-01000837512-2
griseofulvin, united states pharmacopeia (usp) reference standard
griseofulvin, vetranal(tm), analytical standard
griseofulvin permeability diameter, united states pharmacopeia (usp) reference standard
griseofulvin, european pharmacopoeia (ep) reference standard
SR-05000001535-3
SR-05000001535-4
sr-05000001535
SR-05000001535-1
griseofulvin, pharmaceutical secondary standard; certified reference material
HMS3712N13
(2s,6'r)-7-chloro-2',4,6-trimethoxy-6'-methyl-3h-spiro[benzofuran-2,1'-cyclohexan]-2'-ene-3,4'-dione
griseofulvin, british pharmacopoeia (bp) reference standard
(1's,6'r)-7-chloro-2',4,6-trimethoxy-6'-methyl-3h-spiro[benzofuran-2,1'-cyclohex[2]ene]-3,4'-dione
amudane, fulvicin, grisactin
griseofulvin,(s)
107912-37-8
AS-13736
Q416096
BRD-K08273968-001-09-1
BRD-K08273968-001-19-0
griseoflulvin
BT164513
griseofulvin 100 microg/ml in acetonitrile
HY-17583R
CS-0695022
griseofulvin (standard)
Z756424454
griseofulvin (usp-rs)
griseofulvin permeability diameter (usp-rs)
spiro(benzofuran-2(3h),1'-(2)cyclohexene)-3,4'-dione, 7 -chloro-2',4,6-trimethoxy-6'-beta-methyl-
(1's-trans)-7-chloro-2',4,6-trimethoxy-6'-methylspiro(benzofuran-2(3h),1'-cyclohex-2'-ene)-3,4'-dione
griseofulvin oral suspension
griseofulvina (inn-spanish)
griseofulvin (usp:inn)
griseofulvine (inn-french)
7-chloro-4,6-dimethoxycoumaran-3-one-2-spiro-1'-(2'-met hoxy-6'-methylcyclohex-2'-en-4'-one)
griseofulviin (microsize)
griseofulvin (usp:inn:ban:jan)
spiro(benzofuran-2(3h),1'-(2)cyclohexene)-3,4'-dione, 7-chloro-2',4,6-trimethoxy-6'beta-methyl-
ultramicrosize griseofulvin
griseofulvin (microsize)
idifulvin
fulvicin u/f tablets
(2s,6'r)-7-chloro-2',4,6-trimethoxy-6'-methyl-3h,4'h-spiro(1-benzofuran-2,1'-cyclohex(2)ene)-3,4'-dione
7-chloro-2',4,6-trimethoxy-6'-beta-spiro(benzofuran-2(3h), 1'-(2)cyclohexene-3,4'-dione
fulvicin u/f powder
d01aa08
d01ba01
7-chloro-2',4,6-trimethoxy-6'-methylspiro(benzofuran-2(3h),1'-(2)cyclohexene)-3,4'-dione
fulvicin u/f bolus veterinary
ultramicrosize griseofulvin tablets
griseofulvin (ep monograph)
7-chloro-4,6-dimethoxycoumaran-3-one-2-spiro-1'-(2'-methoxy)-6'-methylcyclo-hex-2'-en-4'-one
griseofulvinum (inn-latin)
griseofulvin (usp monograph)
grysio (microsize)
griseofulvin (iarc)
(2s-trans)-7-chloro-2',4,6-trimethoxy-6'-methylspiro
(2s,6'r)-7-chloro-2',4,6-trimethoxy-6'-methylspiro(benzo(b)furan-2(3h),1'-(cyclohex-2'-ene))-3,4'-dione
griseofulvin (mart.)

Research Excerpts

Overview

Griseofulvin is an antifungal polyketide metabolite produced mainly by ascomycetes. It has low aqueous solubility and low oral bioavailability. It was launched in 1962 by Merck & Co.

ExcerptReferenceRelevance
"Griseofulvin (1) is an important antifungal agent that has recently received attention due to its antiproliferative activity in mammalian cancer cells. "( Synthesis and formulation studies of griseofulvin analogues with improved solubility and metabolic stability.
Andersen, NS; Clausen, MH; Hanafiah, NH; Konotop, G; Krämer, A; Petersen, AB; Raab, MS, 2017
)
2.17
"Griseofulvin is a fungal metabolite and antifungal drug used for the treatment of dermatophytosis in both humans and animals. "( Chemoselective fluorination and chemoinformatic analysis of griseofulvin: Natural vs fluorinated fungal metabolites.
Al-Huniti, MH; Burdette, JE; Croatt, MP; Czarnecki, A; González-Medina, M; Medina-Franco, JL; Oberlies, NH; Paguigan, ND; Pearce, CJ; Polyak, SJ; Raja, HA, 2017
)
2.14
"Griseofulvin is an antifungal polyketide metabolite produced mainly by ascomycetes. "( Griseofulvin: An Updated Overview of Old and Current Knowledge.
Aris, P; Mohamadzadeh, M; Wei, Y; Xia, X, 2022
)
3.61
"Griseofulvin (GSF) is an antifungal drug that has low aqueous solubility and low oral bioavailability. "( Could the small molecules such as amino acids improve aqueous solubility and stabilize amorphous systems containing Griseofulvin?
França, MT; Marcos, TM; Pereira, RN; Stulzer, HK, 2020
)
2.21
"Griseofulvin is a well-known antifungal drug that was launched in 1962 by Merck & Co. "( Antibacterial activity of griseofulvin analogues as an example of drug repurposing.
Akrivou, MG; Chatzopoulou, FM; Druzhilovskiy, D; Geronikaki, A; Kartsev, V; Kostic, M; Lichitsky, B; Petrou, A; Poroikov, V; Sirakanyan, S; Smiljkovic, M; Soković, M; Vizirianakis, IS, 2020
)
2.3
"Griseofulvin is a commonly used antifungal agent which is administered per oral (p.o.). "( Nano- and microcrystals of griseofulvin subcutaneously administered to rats resulted in improved bioavailability and sustained release.
Rydberg, H; Sigfridsson, K; Strimfors, M, 2019
)
2.25
"Griseofulvin is an antifungal agent with potential for misuse in food-producing animals. "( Metabolite profiling using liquid chromatography/quadrupole time-of-flight mass spectrometry for the identification of a suitable marker and target matrix of griseofulvin use in bovines.
Fussell, RJ; Tarbin, JA, 2013
)
2.03
"Griseofulvin (1) is a spirocyclic fungal natural product used in treatment of fungal dermatophytes. "( Complexity generation in fungal polyketide biosynthesis: a spirocycle-forming P450 in the concise pathway to the antifungal drug griseofulvin.
Cacho, RA; Chooi, YH; Tang, Y; Zhou, H, 2013
)
2.04
"Griseofulvin is an antifungal drug known to cause drug rash. "( [Severe cutaneous drug reactions to misused griseofulvin: 2 cases].
Kerrad, I; Le Guern, A; Oehler, E, 2016
)
2.14
"Griseofulvin (GRF) is an important antifungal drug with low bioavailability and, for this reason, a topical formulation with a targeted action and minimal systemic effects, appears to be a preferable solution. "( Ethosomes for enhanced skin delivery of griseofulvin.
Ascenso, A; Eleutério, C; Guerreiro, A; Marto, J; Severino, C; Simões, S; Vitor, C, 2016
)
2.14
"Griseofulvin is a small rigid molecule that shows relatively high molecular mobility and small configurational entropy in the amorphous phase and tends to readily crystallize from both rubbery and glassy states. "( Thermodynamics, molecular mobility and crystallization kinetics of amorphous griseofulvin.
Grant, DJ; Law, D; Schmitt, EA; Zhang, GG; Zhou, D,
)
1.8
"Griseofulvin is an orally administered antifungal drug that affects microtubule formation in vitro and interferes with microtubule dynamics in vivo as clearly shown for mitotic cells in several cell systems. "( Effects of griseofulvin on in vitro porcine oocyte maturation and embryo development.
Miao, YL; Murphy, CN; Prather, RS; Schatten, H; Spate, L; Sun, QY; Zhang, X; Zhao, JG; Zhao, MT, 2012
)
2.21
"Griseofulvin is an antifungal substance that interferes with the microtubule apparatus and inhibits centrosomal clustering."( Griseofulvin inhibits the growth of adrenocortical cancer cells in vitro.
Bramann, EL; Haase, M; Hildebrandt, B; Müller-Mattheis, V; Scherbaum, WA; Schott, M; Willenberg, HS, 2013
)
2.55
"Griseofulvin is an antifungal antibiotic having a molecular weight of 353, making it amenable to SC-CO(2) extraction."( Supercritical carbon dioxide extraction of griseofulvin from the solid matrix obtained after solid-state fermentation.
Saykhedkar, SS; Singhal, RS,
)
1.12
"Griseofulvin is a secondary metabolite produced from fungal species that have morphology suitable for solid-state fermentation (SSF). "( Solid-state fermentation for production of griseofulvin on rice bran using Penicillium griseofulvum.
Saykhedkar, SS; Singhal, RS,
)
1.84
"Griseofulvin is an antifungal agent with poor solubility and low bioavailability. "( Preparation and characterization of poly-epsilon-caprolactone nanoparticles containing griseofulvin.
Fessi, H; Sfar, S; Zili, Z, 2005
)
1.99
"Griseofulvin is a classical oral fungistatic antibiotic, active against Epidermophyton floccosum, Trichophyton and Microsporum species, the causative fungi of tinea corporis."( Efficacy of topical griseofulvin in treatment of tinea corporis.
Bendas, ER; El-Komy, MH; Esmat, S; Kassem, MA, 2006
)
1.38
"Griseofulvin (GF) is an oral antibiotic for widely occurring superficial mycosis in man and animals caused by dermaphyte fungi; it is also used in agriculture as a fungicide. "( Interactions of a fungistatic antibiotic, griseofulvin, with phospholipid monolayers used as models of biological membranes.
Badis, M; Barzyk, W; Brezesinski, G; Corvis, Y; Hecht, S; Mrabet, N; Rogalska, E, 2006
)
2.04
"Griseofulvin (GF) is a widely used antifungal drug for the treatment of superficial dermatomycoses. "( Induction of kinetochore-positive micronuclei in human lymphocytes by the anti-fungal drug griseofulvin.
Kolachana, P; Smith, MT, 1994
)
1.95
"Griseofulvin is an anti-fungal drug whose mechanism of action is directed against microtubules. "( Griseofulvin: a novel interaction with bovine brain tubulin.
Chaudhuri, AR; Ludueña, RF, 1996
)
3.18
"Griseofulvin is a poorly soluble antifungal antibiotic drug, the solubility of which can be enhanced by complexation with beta-cyclodextrin. "( Enhancement of bioavailability of griseofulvin by its complexation with beta-cyclodextrin.
Baskaran, T; Dhanaraju, MD; Kumaran, KS; Moorthy, MS, 1998
)
2.02
"Griseofulvin (GF) is a poor water soluble, antifungal agent. "( Production of griseofulvin nanoparticles using supercritical CO(2) antisolvent with enhanced mass transfer.
Chattopadhyay, P; Gupta, RB, 2001
)
2.11
"Griseofulvin is a metabolic product of Penicillium spp. "( [Griseofulvin].
Develoux, M, 2001
)
2.66
"Griseofulvin (GF) is a fungicide drug well characterized for its aneugenic activity in vitro. "( Griseofulvin induces mitotic delay and aneuploidy in bone marrow cells of orally treated mice.
Bassani, B; Marchetti, F; Pacchierotti, F; Tiveron, C, 2002
)
3.2
"Griseofulvin is an orally acting anti-fungal antibiotic with very limited water solubility. "( Structure modification and biological activity of some griseofulvin derivatives.
Currie, BL; De Croos, PZ; Delgado, L; Lu, MC, 1992
)
1.97
"Griseofulvin (GF) is a mycotoxin produced by various species of Penicillium including P. "( Griseofulvin.
De Carli, L; Larizza, L, 1988
)
3.16

Effects

Griseofulvin (GF) has similar chemical features as compared to ciclopirox olamine. It has been the treatment of choice for tinea capitis for more than 40 years and is the sole oral antifungal agent approved by the FDA for the management of tinea Capitis.

ExcerptReferenceRelevance
"Griseofulvin has been the treatment of choice for tinea capitis for more than 40 years and is the sole oral antifungal agent approved by the FDA for the management of tinea capitis."( In vitro pharmacodynamic characteristics of griseofulvin against dermatophyte isolates of Trichophyton tonsurans from tinea capitis patients.
Gupta, AK; Singh, J; Williams, JV; Zaman, M, 2009
)
1.34
"Griseofulvin has been the mainstay of treatment for dermatophytosis since many years. "( Prescription auditing of griseofulvin in a tertiary care teaching hospital.
Bai Kirubha, MH,
)
1.88
"Griseofulvin (GF) has similar chemical features as compared to ciclopirox olamine."( In vivo efficacy of griseofulvin against multiple myeloma.
Alpmann, P; Blaum-Feder, S; Carson, D; Endo, T; Kim, Y; Krämer, S; Lu, D; Schmidt-Wolf, IG, 2011
)
1.41
"Griseofulvin has been the standard treatment for tinea capitis but newer antifungal agents, particularly terbinafine, are increasingly being used because of their shorter duration of treatment and more consistent absorption rates."( Meta-analysis of randomized, controlled trials comparing griseofulvin and terbinafine in the treatment of tinea capitis.
Chan, YC; Tan, AS; Tey, HL, 2011
)
2.06
"Griseofulvin has been the mainstay of treatment for tinea imbricata (TI) for decades; however, there have been few reports of efficacy of newer antifungals in the treatment of this condition. "( Treatment of tinea imbricata: a randomized clinical trial using griseofulvin, terbinafine, itraconazole and fluconazole.
Fernandez-Obregon, AC; Greer, DL; Wignall, FS; Wingfield, AB, 2004
)
2
"Griseofulvin has been the mainstay of treatment for many years."( Therapeutic options for the treatment of tinea capitis: griseofulvin versus fluconazole.
Azizzadeh, M; Dastghaib, L; Jafari, P, 2005
)
1.3
"Griseofulvin has been used in the treatment of toenail onychomycosis with limited success. "( Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis.
Anderson, C; Faergemann, J; Hersle, K; Hradil, E; Kaaman, T; Molin, L; Nordin, P; Pettersson, A, 1995
)
1.98
"Griseofulvin has been considered to be a first-line therapy."( Itraconazole versus griseofulvin in the treatment of tinea capitis: a double-blind randomized study in children.
Del Palacio, A; Iglesias, L; López-Gómez, S; Rodriguez-Noriega, A; Soledad Cuétara, M; Van Cutsem, J, 1994
)
1.33
"Oral griseofulvin has been the first-line drug in the therapy of dermatophyte onychomycosis for many years. "( Oral therapeutic agents in fungal nail disease.
Roberts, DT, 1994
)
0.8
"Griseofulvin has been incorporated into these microspheres and its physical characterization has been carried out by differential scanning calorimetry (DSC), X-ray diffractometry and X-ray photoelectron spectroscopy."( Formulation and evaluation of vinylpyrrolidone/vinylacetate copolymer microspheres with griseofulvin.
Bogataj, M; Mrhar, A; Rubessa, F; Vojnovic, D,
)
1.07
"Griseofulvin (GF) has been in use for more than 30 years as a pharmaceutical drug in humans for the treatment of dermatomycoses. "( Toxic effects of griseofulvin: disease models, mechanisms, and risk assessment.
Ecker, S; Helma, C; Kassie, F; Knasmüller, S; Parzefall, W; Schulte-Hermann, R, 1997
)
2.08
"Griseofulvin has traditionally served as the standard of care for scalp and nail infections, but an increasing proportion of tinea capitis infections are proving refractory or very slowly responsive to treatment."( Pediatric antifungal therapy.
Friedlander, SF; Suarez, S, 1998
)
1.02
"Griseofulvin has been the mainstay of therapy for the last 40 years."( Tinea capitis: an overview with emphasis on management.
Adam, P; Gupta, AK; Hofstader, SL; Summerbell, RC,
)
0.85
"Griseofulvin has been used for many years in the treatment of tinea capitis. "( Comparison of terbinafine and griseofulvin in the treatment of tinea capitis.
Ballona, R; Bustamante, B; Cáceres-Ríos, H; Rueda, M, 2000
)
2.04
"Griseofulvin has been used as an antifungal drug for many years, but it has recently been shown effective for several inflammatory skin diseases. "( Griseofulvin has a potential to modulate the expression of cell adhesion molecules on leukocytes and vascular endothelial cells.
Asahina, A; Nakamura, K; Tada, Y; Tamaki, K, 2001
)
3.2
"Griseofulvin has been the mainstay of management."( Therapeutic options for the treatment of tinea capitis caused by Trichophyton species: griseofulvin versus the new oral antifungal agents, terbinafine, itraconazole, and fluconazole.
Aboobaker, J; Adam, P; Dlova, N; Gupta, AK; Hofstader, S; Lynde, CW; Morar, N; Summerbell, RC,
)
1.08
"Griseofulvin has also anti-inflammatory properties and some direct vasodilatory effects when it is used in high doses."( [Griseofulvin].
Develoux, M, 2001
)
1.94
"Griseofulvin(GF) has become the drug of choice as an antifungal agent for patients who suffer from many kinds of fungal infection. "( Effect of ursodeoxycholic acid on experimental hepatic porphyria induced by griseofulvin.
Cho, HM; Choi, SW; Chung, KW; Han, JH; Kim, BS; Lim, KT; Park, DH; Seo, EJ; Sun, HS, 1991
)
1.95
"Griseofulvin has been used to improve the clinical appearances in eumycetoma (fungal mycetoma) cases which respond poorly to antifungal chemotherapy and it is suggested that its effect in this condition depends, in part, on its ability to inhibit leucocyte aggregation around mycetoma grains."( Leucocyte chemotaxis to mycetoma agents--the effect of the antifungal drugs griseofulvin and ketoconazole.
Hay, RJ; Yousif, MA, 1987
)
1.22

Actions

ExcerptReferenceRelevance
"Oral griseofulvin induced an increase in mitochondrial cytochrome P-450 levels, while chronic Isoflurane produced a reduction on its levels, without alterations on microsomal cytochrome P-450."( Metabolization of porphyrinogenic agents in brain: involvement of the phase I drug metabolizing system. A comparative study in liver and kidney.
Batlle, AM; Buzaleh, AM; Lavandera, JV, 2007
)
0.79

Treatment

Griseofulvin was withdrawn from the Belgian market in 1997. It is still the treatment of choice for cases caused by Microsporum species.

ExcerptReferenceRelevance
"Griseofulvin has been the treatment of choice for tinea capitis for more than 40 years and is the sole oral antifungal agent approved by the FDA for the management of tinea capitis."( In vitro pharmacodynamic characteristics of griseofulvin against dermatophyte isolates of Trichophyton tonsurans from tinea capitis patients.
Gupta, AK; Singh, J; Williams, JV; Zaman, M, 2009
)
1.34
"Griseofulvin is still the treatment of choice for cases caused by Microsporum species."( Guidelines for the management of tinea capitis in children.
Kakourou, T; Uksal, U,
)
0.85
"Griseofulvin, the gold treatment, was withdrawn from the Belgian market in 1997."( [How to cope with tinea capitis?].
Lateur, N, 2004
)
1.04
"Griseofulvin treatment of mice leads to a significant increase of transglutaminase activity associated with the 105 000 X g supernatant of liver homogenate, which is readily reversible after replacement of the griseofulvin-containing diet by a normal diet."( Effect of griseofulvin treatment and neoplastic transformation on transglutaminase activity in mouse liver.
Bernklau, G; Denk, H; Krepler, R, 1984
)
1.39
"In griseofulvin-treated mice, typical Mallory bodies were observed as randomly oriented, relatively short, approximately 17-nm."( Relationship of Mallory bodies to the cytoskeleton of hepatocytes in griseofulvin-treated mice.
Benson, NC; French, SW; Irie, T, 1982
)
1.01
"Griseofulvin treatment for 4 days led to marked elevation of the activity of 5-aminolevulinate synthase in peritumoral (3.8-fold) and control (6-fold) liver."( Effect of Griseofulvin on 5-aminolevulinate synthase and on ferrochelatase in mouse liver neoplastic nodules.
Abdelfattach-Gad, M; Denk, H; Kalt, R; Meyer, UA, 1981
)
1.39
"Griseofulvin treatment was cheapest but required the longest treatment course."( [Oral treatment of onychomycosis of the toe nails; comparison of cost-effectiveness of griseofulvin, itraconazole, ketoconazole and terbinafine].
Bergman, W; Rutten, FF, 1994
)
1.23
"Griseofulvin is the treatment of choice today."( [Recent findings in dermatophytic skin diseases (author's transl)].
Götz, H, 1978
)
0.98
"Griseofulvin-treated patients were treated for shorter periods than terbinafine-treated patients (i.e."( A comparative double-blind study of terbinafine (Lamisil) and griseofulvin in tinea corporis and tinea cruris.
del Palacio Hernandez, A; González Lastra, F; Iglesias Díez, L; López Gómez, S; Moreno Palancar, P, 1990
)
1.24
"Treatment with griseofulvin suspension for 12 weeks was compared with (a) griseofulvin suspension for 8 weeks and with (b) terbinafine tablets for 4 weeks."( Griseofulvin vs terbinafine for paediatric tinea capitis: When and for how long.
Bar, J; Mashiah, J; Samuelov, L; Sprecher, E, 2019
)
2.3
"Treatment with griseofulvin was satisfactory in all cases."( Tinea capitis outbreak among paediatric refugee population, an evolving healthcare challenge.
Ben Ami, R; Gan Or, T; Goldberg, I; Harel, A; Kutz, A; Mashiah, J; Savion, M; Sprecher, E; Zidan, O, 2016
)
0.77
"Treatment with griseofulvin significantly improves the QOL in patients with dermatophytosis."( Prescription auditing of griseofulvin in a tertiary care teaching hospital.
Bai Kirubha, MH,
)
0.77
"Treatment with Griseofulvin was commenced, and complete resolution of the lesion occurred."( Ringworm causing childhood preseptal cellulitis.
Evans, SL; Morton, CE; Ng, CS; Rajalekshmi, PS; Williams, RE, 2003
)
0.66
"Treatment with griseofulvin and tolnaftate cured the lesions in 6 weeks."( [Dermatophytosis caused by Aphanoascus fulvescens].
Campos, R; Marín, G, 1984
)
0.61
"Treatment of griseofulvin alone gave rise to hepatitis with the presence of Mallory bodies (MB) whereas the same length of treatment with Perhexilin Maleate was associated with steatonecrosis with an absence of MB."( [Comparative hepatic toxicity of perhexiline maleate and griseofulvin in mice].
Boucard, M; François, C; Michel, H; Sablier, G; Sentein, P; Vic, P, 1981
)
0.86
"Treatment with griseofulvin alone resulted in clearing of the fungal infection and improvement of his papuloerythroderma, and, worsening of his papuloerythroderma occurred when the tinea relapsed."( Papuloerythroderma of Ofuji: a report of three cases and review of the literature.
Ong, BH; Tan, KC; Tay, YK; Wong, WK, 1994
)
0.63
"Treatment with griseofulvin over prolonged periods of time resulted in the dissociation of cytokeratin filaments from the plasma membrane and the inclusions of cytokeratin material in typical cytoplasmic aggregates, i.e."( Maintenance of desmosomes in mouse hepatocytes after drug-induced rearrangement of cytokeratin filament material. Demonstration of independence of desmosomes and intermediate-sized filaments.
Cowin, P; Denk, H; Franke, WW; Lackinger, E, 1985
)
0.61
"Retreatment with griseofulvin again resulted in clearing."( Erythema dyschromicum perstans and lichen planus: are they related?
Berger, RS; Dixon, SL; Hayes, TJ, 1989
)
0.61

Toxicity

Two itraconazole patients stopped medication due to an adverse event. In the griseofulvin group 15 patients (12.5%) had treatment related adverse events.

ExcerptReferenceRelevance
" Two itraconazole patients stopped medication due to an adverse event, compared to four patients in the griseofulvin group."( Efficacy and safety of itraconazole in the long-term treatment of onychomycosis.
Blomqvist, K; Brandt, H; Havu, V; Hollmen, A; Kohtamäki, K; Lehtonen, L; Piepponen, T; Turjanmaa, K, 1992
)
0.5
" Zearalenone was about 3 times more toxic than its analogue zearalenol."( Toxicity of trichothecenes, moniliformin, zearalenone/ol, griseofulvin, patulin, PR toxin and rubratoxin B on protozoan tetrahymena pyriformis.
Cole, RJ; Cutler, HG; Nishie, K, 1989
)
0.52
" Some of these inhibitors (namely, colchicine, vinblastine, taxol, and maytansine) were found to exhibit large (between tenfold and fiftyfold) differences in their toxic and antimitotic concentrations toward various cell lines and these differences appeared to be species related inasmuch as all cell lines from a particular species showed similar sensitivities toward these inhibitors."( Species-specific differences in toxicity of antimitotic agents toward cultured mammalian cells.
Gupta, RS, 1985
)
0.27
" These studies in part led to a more thorough description of possible adverse effects or even restrictions for use."( OTC pharmaceuticals and genotoxicity testing: the paracetamol, anthraquinone, and griseofulvin cases.
Kasper, P; Müller, L, 1995
)
0.52
"5%) had treatment related adverse events and in the griseofulvin group 15 patients (12."( A multicentre (double-blind) comparative study to assess the safety and efficacy of fluconazole and griseofulvin in the treatment of tinea corporis and tinea cruris.
Faergemann, J; Haglund, A; Mörk, NJ; Odegård, T, 1997
)
0.76
" Animal studies give clear evidence that it causes a variety of acute and chronic toxic effects, including liver and thyroid cancer in rodents, abnormal germ cell maturation, teratogenicity, and embroyotoxicity in various species."( Toxic effects of griseofulvin: disease models, mechanisms, and risk assessment.
Ecker, S; Helma, C; Kassie, F; Knasmüller, S; Parzefall, W; Schulte-Hermann, R, 1997
)
0.64
" The extracts were however found to be relatively non-toxic as each extract had an LD50 value greater than 1000 microg/ml."( Preliminary antifungal and cytotoxicity studies of extracts of Ritchiea capparoides var. longipedicellata.
Ajaiyeoba, EO; Choudhary, IM; Rahman, AU, 1998
)
0.3
" Terbinafine has been shown to be effective and safe in several studies of the treatment of tinea capitis and onychomycosis in children."( The efficacy and safety of terbinafine in children.
Cooper, EA; Gupta, AK; Lynde, CW, 2003
)
0.32
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016
)
0.43
" Mycological cure rate was the primary outcome; complete cure rate and adverse events were secondary outcomes."( A network meta-analysis on the efficacy and safety of monotherapies for tinea capitis, and an assessment of evidence quality.
Bamimore, MA; Gupta, AK; Piguet, V; Renaud, HJ; Shear, NH, 2020
)
0.56
" Visual and histological examinations of the skin in healthy rabbits showed no obvious adverse effects after US-assisted application of the Gf-loaded carriers."( Cytotoxicity, Dermal Toxicity, and In Vivo Antifungal Effect of Griseofulvin-Loaded Vaterite Carriers Administered via Sonophoresis.
Bosak, IA; Bucharskaya, AB; Kozlova, AA; Lengert, EV; Makarkin, MA; Mylnikov, AM; Navolokin, NA; Saveleva, MS; Svenskaya, YI; Terentyuk, GS; Vasilyeva, NV; Verkhovskii, RA, 2023
)
1.15

Pharmacokinetics

ExcerptReferenceRelevance
" Based on the pharmacokinetic profile, 100 mg itraconazole daily was then compared with 500 mg ultramicronized griseofulvin daily using a fixed treatment schedule of 15 days in tinea corporis and/or cruris and 30 days in tinea pedis and/or manus."( Itraconazole compared with griseofulvin in the treatment of tinea corporis/cruris and tinea pedis/manus: an interpretation of the clinical results of all completed double-blind studies with respect to the pharmacokinetic profile.
Cauwenbergh, G; De Doncker, P; Janssen, PA; Lachapelle, JM; Tennstedt, D, 1992
)
0.79
" Time to peak concentration in cutis was shorter (20 min; 13."( Pharmacokinetics of griseofulvin in blood and skin suction blister fluid of rats.
Schäfer-Korting, M,
)
0.45
" These results suggest the need for cautious interpretation of some venous pharmacokinetic data."( Instantaneous input hypothesis in pharmacokinetic studies.
Chen, ML; Chiou, WL; Lam, G; Lee, MG, 1981
)
0.26
" Detailed analyses showed significant differences in various calculated pharmacokinetic parameters based on arterial or venous data."( Arterial and venous blood sampling in pharmacokinetic studies: griseofulvin.
Chen, ML; Chiou, WL; Lam, G; Lee, MG, 1982
)
0.5
"The present investigation aims to establish efficacious screening strategy to clarify the phototoxic potential of pharmaceutical substances and its possible pathways by characterizing both photobiochemical properties and pharmacokinetic profiles."( In vitro/in vivo phototoxic risk assessments of griseofulvin based on photobiochemical and pharmacokinetic behaviors.
Onoue, S; Seto, Y; Yamada, S, 2009
)
0.61
" Pretreatment of the rats with thylakoid-rich spinach extract (100 or 300 mg/kg) for 15 min prior to oral administration of GF (50 mg/kg) or IM (10 mg/kg) did not significantly alter the pharmacokinetic properties of either drug."( Effects of Thylakoid-Rich Spinach Extract on the Pharmacokinetics of Drugs in Rats.
Katoh, M; Nadai, M; Saito, Y; Usami, T, 2019
)
0.51

Compound-Compound Interactions

ExcerptReferenceRelevance
"Oral contraceptives (OCs) should be used with additional caution in combination with other drugs in certain disease states."( Drug interactions with oral contraceptive preparations.
Shenfield, GM, 1986
)
0.27
"A parallel-group double-blind study was carried out which compared the efficacy of chemical avulsion of affected nail by urea 40% and bifonazole 1% cream alone with that of the same local therapy combined with short-term oral griseofulvin in onychomycosis."( Treatment of onychomycosis: a randomized, double-blind comparison study with topical bifonazole-urea ointment alone and in combination with short-duration oral griseofulvin.
Bergman, R; Bitterman, O; Cohen, A; Friedman-Birnbaum, R; Shemer, A; Stettendorf, S, 1997
)
0.68

Bioavailability

The effects of hexadecane, oleyl alcohol, polysorbate 80, trioctanoin, and triolein on the bioavailability of sulfisoxazole N1-acetyl, dicumarol, and griseofulvin were investigated. The results of the in vivo study show the formulation technique has increased the rate and extent of bioavailability.

ExcerptReferenceRelevance
" The results of the in vivo study show the formulation technique has increased the rate and extent of bioavailability of griseofulvin when compared with the non-treated powder."( Bioavailability of griseofulvin from a novel capsule formulation.
Calvert, RT; Fell, JT; Riley-Bentham, P, 1978
)
0.79
"The effects of hexadecane, oleyl alcohol, polysorbate 80, trioctanoin, and triolein on the bioavailability of sulfisoxazole N1-acetyl, dicumarol, and griseofulvin were investigated."( Effects of lipids on bioavailability of sulfisoxazole acetyl, dicumarol, and griseofulvin in rats.
Bloedow, DC; Hayton, WL, 1976
)
0.68
"The correlation between the dissolution rate and bioavailability of griseofulvin tablets was studied in stomach-emptying-controlled rabbits and in humans."( Use of rabbits for GI drug absorption studies: relationship between dissolution rate and bioavailability of griseofulvin tablets.
Maeda, T; Noguchi, T; Takenaka, H; Yamahira, Y, 1979
)
0.71
"The intestinal absorption rate of dissolved griseofulvin was determined from: (a) an aqueous phase, (b) an aqueous phase containing a micellar phase composed of taurodeoxycholate, monoolein, and oleic acid, and (c) an aqueous phase containing the micellar phase and emulsified triolein."( Intestinal absorption of griseofulvin from a triolein digestion mixture in rats.
Grisafe, JA; Hayton, WL, 1978
)
0.82
" When premicellar concentrations of butyric, octanoic, or dodecanoic acid were present in the perfusate, the griseofulvin absorption rate decreased while that of prednisolone increased."( Effects of short and medium chain fatty acids on absorption of lipophilic drugs from perfused rat intestine.
Grisafe, JA; Hayton, WL, 1978
)
0.47
" Applications are given to a comparative bioavailability trial for attainment of steady state levels and to a clinical trial to compare the effects of two hypolipidemics."( The analysis of the two-period repeated measurements crossover design with application to clinical trials.
Fisher, AC; Wallenstein, S, 1977
)
0.26
" As compared to either the aqueous suspension, Tablet A, or Tablet B, three- to fourfold increases in the maximum body levels and a twofold enhancement in the bioavailability of the antibiotic were observed after administration of the emulsion dosage form."( Bioavailability of micronized griseofulvin from corn oil-in-water emulsion, aqueous suspension, and commercial tablet dosage forms in humans.
Bates, TR; Sequeria, JA, 1975
)
0.54
"The dissolution procedure serves as a quality control test to assure batch-to-batch uniformity and bioequivalence of a product once the bioavailability of the product has been established."( Influence of higher rates of agitation on release patterns of immediate-release drug products.
Dighe, S; Gurbarg, M; Noory, A; Shah, VP; Skelly, JP, 1992
)
0.28
" Parameters of bioavailability have been found on the basis of the changes in griseofulvin plasma concentrations versus time."( [Bioavailability of griseofulvin in the form of liposomes].
Borysiewicz, J; Stozek, T, 1991
)
0.83
" Therefore, it is concluded that coadministration of griseofulvin with food will tend to reduce the difference between the bioavailability of the two type of preparations."( The bioavailability of griseofulvin from microsized and ultramicrosized tablets in nonfasting volunteers.
Bijanzadeh, M; Eshghi, L; Khazainia, T; Khosravy, A; Mahmoudian, M; Salehian, P, 1990
)
0.84
" Concentrations of TC above the critical micelle concentration (CMC) did not affect the absorption rate of the hydrophilic drugs PA and TP; the barrier function of the intestinal wall for PA and TP was not altered in the presence of taurocholate."( Intestinal absorption of drugs. III. The influence of taurocholate on the disappearance kinetics of hydrophilic and lipophilic drugs from the small intestine of the rat.
Breäs, R; Poelma, FG; Tukker, JJ, 1990
)
0.28
"The bioavailability of griseofulvin was followed in twelve healthy volunteers by measuring the urinary excretion of the major metabolite 6-demethylgriseolfulvin, after each volunteer had ingested one 500 mg griseofulvin tablet under (1) fasting conditions, (2) immediately after a typical low-fat and (3) high-fat Nigerian meals."( Fat contents of meals and bioavailability of griseofulvin in man.
Ogunbona, FA; Olawoye, OS; Smith, IF, 1985
)
0.84
" Bile salts and a varying quantity of lipid perfusate had no significant influence on the duodeno-jejunal griseofulvin absorption rate per cm of intestine."( Influence of bile salts and lipids on intestinal absorption of griseofulvin in man.
Barre, J; Bernier, JJ; Houin, G; Palma, R; Pfeiffer, A; Rongier, M; Vidon, N, 1986
)
0.72
" The model correctly predicts bioavailability as a function of particle size for both of these poorly soluble drugs."( Mixing-tank model for predicting dissolution rate control or oral absorption.
Dressman, JB; Fleisher, D, 1986
)
0.27
" The bioavailability of griseofulvin was higher following the ultramicrosize formulation when 64% of the dose was recovered (via metabolites) versus 52% after the microsize preparation."( Human plasma and skin blister fluid levels of griseofulvin following a single oral dose.
Korting, HC; Mutschler, E; Schäfer-Korting, M, 1985
)
0.83
"The bioavailability of griseofulvin in three different brands, two microfine forms (Gricin = G, Likuden = L), and one ultramicrofine form (Gris-PEG = GP), was determined in plasma and urine in six healthy volunteers in a crossover study and compared with in vitro liberation data."( The in vitro liberation and the bioavailability of different brands of griseofulvin in plasma and urine in man.
Feller, K; Le Petit, G; Pachaly, C; Terhaag, B, 1985
)
0.81
" On repeated administration, the bioavailability of griseofulvin was significantly lower from the microsize formulation; the urinary recovery of total 6-DMG was 33."( Human plasma and skin blister fluid levels of griseofulvin after its repeated administration.
Korting, HC; Mutschler, E; Schäfer-Korting, M, 1985
)
0.78
" The bioavailability of an ultramicronized formulation in rabbits was higher after the postprandial dose than after the preprandial dose."( Bioavailability of griseofulvin plain tablets in stomach-emptying controlled rabbits and the correlation with bioavailability in humans.
Aoyagi, N; Ejima, A; Kaniwa, N; Ogata, H, 1984
)
0.6
" The bioavailability of four griseofulvin tablets used in a human bioavailability study was investigated in the pigs and compared with the human results."( Bioavailability of griseofulvin from plain tablets in Göttingen minipigs and the correlation with bioavailability in humans.
Aoyagi, N; Ejima, A; Kaniwa, N; Ogata, H; Tanioka, Y; Yasuda, Y, 1984
)
0.89
"Effect of food on the bioavailability of griseofulvin from its two plain tablets, a commercial microsize product and a PEG ultramicrosize (GRIS-PEGR) one, was investigated."( Effect of food on the bioavailability of griseofulvin from microsize and PEG ultramicrosize (GRIS-PEG) plain tablets.
Aoyagi, N; Ejima, A; Kaniwa, N; Ogata, H, 1982
)
0.8
"The bioavailability of 500 mg of a microsize formulation of griseofulvin has been compared to two new ultramicrosize griseofulvin formulations, two 165 mg tablets and a 330 mg tablet, in sixteen healthy, male, volunteers in a randomized crossover study design."( Comparative bioavailability of a microsize and ultramicrosize griseofulvin formulation in man.
DiGiore, C; Gural, R; Lim, J; Lin, C; Symchowicz, S, 1982
)
0.75
" The products, three microsize and one ultramicrosize, were selected for further studies on the bioavailability in humans and dissolution."( Bioavailability of griseofulvin from tablets in humans and the correlation with its dissolution rate.
Aoyagi, N; Ejima, A; Kaniwa, N; Koibuchi, M; Ogata, H; Shibazaki, T, 1982
)
0.59
"The bioavailability of four griseofulvin tablets in beagle dogs, including an ultramicrosize tablet used previously in a human bioavailability study, was investigated on the basis of the plasma 6-demethyl-griseofulvin concentration."( Bioavailability of griseofulvin from tablets in beagle dogs and correlation with dissolution rate and bioavailability in humans.
Aoyagi, N; Ejima, A; Kamimura, H; Kaniwa, N; Katougi, Y; Koibuchi, M; Ogata, H; Omi, Y; Shibazaki, T; Tamaki, N, 1982
)
0.89
"A controlled crossover study was carried out on five volunteers to substantiate reported effects of fat intake on the bioavailability of griseofulvin."( Influence of high fat diet on GI absorption of griseofulvin tablets in man.
Elgholmy, ZA; Khalafalla, N; Khalil, SA, 1981
)
0.72
"The relative bioavailability of ten marketed dosage forms of griseofulvin was evaluated in two separate crossover studies."( Bioavailability of microsize and ultramicrosize griseofulvin products in man.
Meyer, MC; Raghow, G; Rotenberg, K; Straughn, AB, 1980
)
0.76
"A bioavailability study was carried out in man on five brands of griseofulvin tablets."( Bioavailability of different brands of griseofulvin tablets and its correlation to dissolution data.
Elgholmy, ZA; Khalafalla, N; Khalil, SA, 1980
)
0.77
" Absorption rate was strongly correlated to the amount of griseofulvin offered to the test segment per unit time."( Griseofulvin absorption from different sites in the human small intestine.
Gramatté, T, 1994
)
1.98
" The drug concentrations were obtained by convoluting the drug absorption rate quadratic function with the drug disposition model function."( DeMonS--a new deconvolution method for estimating drug absorbed at different time intervals and/or drug disposition model parameters using a monotonic cubic spline.
Gupta, SK; Hwang, SS; Yu, Z, 1997
)
0.3
" For each drug, micronization improved their digestive absorption, and consequently their bioavailability and clinical efficacy."( Micronization: a method of improving the bioavailability of poorly soluble drugs.
Chaumeil, JC, 1998
)
0.3
" The bioavailability of the drug and its absorption from the gastrointestinal tract can be greatly improved by particle size reduction."( Production of griseofulvin nanoparticles using supercritical CO(2) antisolvent with enhanced mass transfer.
Chattopadhyay, P; Gupta, RB, 2001
)
0.67
" Griseofulvin is poorly absorbed from the gastrointestinal tract."( [Griseofulvin].
Develoux, M, 2001
)
2.13
" We conclude that GF induces mitotic delay and aneuploidy in mouse bone marrow and suggest that the protocol used to formulate the gavage suspensions and the after-treatment fasting of the animals enhanced the bioavailability of GF to bone marrow cells."( Griseofulvin induces mitotic delay and aneuploidy in bone marrow cells of orally treated mice.
Bassani, B; Marchetti, F; Pacchierotti, F; Tiveron, C, 2002
)
1.76
" The dissolution rate of griseofulvin nanoparticles was higher than that of micronized griseofulvin therefore recourse to nanoencapsulation of griseofulvin should enhance its bioavailability and possibly its efficiency for the treatment of dermatomycosis."( Preparation and characterization of poly-epsilon-caprolactone nanoparticles containing griseofulvin.
Fessi, H; Sfar, S; Zili, Z, 2005
)
0.85
" The aim of this study was to improve the dissolution rate and subsequently the oral absorption and bioavailability of a model poorly water-soluble drug."( Enhancement of the dissolution rate and oral absorption of a poorly water soluble drug by formation of surfactant-containing microparticles.
Kellaway, IW; Murdan, S; Wong, SM, 2006
)
0.33
" It is generally believed that the in-vivo bioavailability of poorly water-soluble drugs from Class II of the Biopharmaceutics Classification System can be improved by increasing the dissolution rate."( Fast-dissolving microparticles fail to show improved oral bioavailability.
Kellaway, IW; Murdan, S; Wong, SM, 2006
)
0.33
" Thereafter, to evaluate the ability of these in vitro and ex vivo results to predict the corresponding in vivo oral bioavailability data."( The effect of different lipid based formulations on the oral absorption of lipophilic drugs: the ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats.
Dahan, A; Hoffman, A, 2007
)
0.34
" The LDE tablets were prepared by freeze-drying o/w emulsions of GF, a drug for which bioavailability is known to be enhanced by fat co-administration."( In vitro and in vivo evaluation of a fast-disintegrating lyophilized dry emulsion tablet containing griseofulvin.
Aboul-Einien, MH; Ahmed, IS, 2007
)
0.56
" However, food intake effect on the bioavailability of griseofulvin has remained."( Improving the high variable bioavailability of griseofulvin by SEDDS.
Al-Tabakha, MM; Arida, AI; Hamoury, HA, 2007
)
0.84
"The oral bioavailability of griseofulvin (GF) formulated as a fast disintegrating lyophilized dry emulsion (LDE) tablet was studied and compared to the commercially available immediate release (IR) tablet, as a reference, in both the fasted and fed states in nine healthy volunteers after a single oral dose (125 mg) in a crossover design."( Relative bioavailability of griseofulvin lyophilized dry emulsion tablet vs. immediate release tablet: a single-dose, randomized, open-label, six-period, crossover study in healthy adult volunteers in the fasted and fed states.
Aboul-Einien, MH; Ahmed, IS; Farid, SF; Mohamed, OH, 2008
)
0.93
"The effect of oil-in-water submicron emulsion (SE) droplet surface charge on absolute bioavailability of a poorly water-soluble drug (griseofulvin, as model drug) after oral administration was studied in conscious rat."( Effect of oil-in-water submicron emulsion surface charge on oral absorption of a poorly water-soluble drug in rats.
Barthélémy, C; Brossard, D; Crauste-Manciet, S; Farinotti, R; Muhamed, S; Nicolaos, G; Odou, P; Poullain-Termeau, S; Robert, H, 2008
)
0.55
"We have attempted to micronize drug particles with a particle size of less than 100 nm and maintain the particle size of their suspension to improve the solubility and bioavailability of poorly water-soluble drugs."( Preparation of griseofulvin nanoparticle suspension by high-pressure homogenization and preservation of the suspension with saccharides and sugar alcohols.
Arakawa, M; Kamiya, S; Kurita, T; Miyagishima, A, 2009
)
0.71
"The aim of the present report was to develop nonionic surfactant vesicles (niosomes) to improve poor and variable oral bioavailability of griseofulvin."( Enhanced oral bioavailability of griseofulvin via niosomes.
Gajbhiye, KR; Gajbhiye, V; Ganesh, N; Jadon, PS; Jadon, RS, 2009
)
0.84
" A new approach was developed for promoting drug bioavailability that has the potential to decrease the required dose and side effects, particularly for chemotherapeutic drugs with narrow therapeutic index."( The development of a dense gas solvent exchange process for the impregnation of pharmaceuticals into porous chitosan.
Barrett, A; Dehghani, F; Foster, NR; Ji, C; Poole-Warren, LA, 2010
)
0.36
" The clinical failure of the conventional oral therapy of griseofulvin is most likely attributed to its poor solubility and appreciable inter- and intra-subject variation in bioavailability from different commercial products."( Preparation and evaluation of dermal delivery system of griseofulvin containing vitamin E-TPGS as penetration enhancer.
Aggarwal, N; Goindi, S; Mehta, SD, 2012
)
0.87
"The improvement of the bioavailability of poorly soluble drugs has been an important issue in pharmaceutical research for many years."( Solid crystal suspensions containing griseofulvin--preparation and bioavailability testing.
Neubert, RH; Reitz, E; Thommes, M; Vervaet, C, 2013
)
0.66
"Drug polymer-based amorphous solid dispersions (ASD) are widely used in the pharmaceutical industry to improve bioavailability for poorly water-soluble compounds."( In vitro and in vivo evaluation of amorphous solid dispersions generated by different bench-scale processes, using griseofulvin as a model compound.
Bao, L; Chiang, PC; Chou, KJ; Cui, Y; Deng, Y; Hau, J; Jia, W; La, H; Lubach, J; Qin, A; Ran, Y; Sambrone, A; Wong, H, 2013
)
0.6
" Overall, our research provides an elegant opportunity for developing effective drug carriers with stable network toward enhancing and/or controlling bioavailability and extending shelf-life of drug molecules using GRAS excipients, food polysaccharides, that are inexpensive and non-toxic."( Organized polysaccharide fibers as stable drug carriers.
Campanella, OH; Gill, KL; Janaswamy, S; Pinal, R, 2013
)
0.39
"It is well known that large differences exist in the bioavailability of orally administered drugs between species."( Species differences in the dissolution and absorption of griseofulvin and albendazole, biopharmaceutics classification system class II drugs, in the gastrointestinal tract.
Nagata, S; Tanaka, Y; Waki, R, 2013
)
0.64
" These positive attributes can help development of smaller, high drug-loaded dosage forms having enhanced bioavailability and better patient compliance."( Redispersible fast dissolving nanocomposite microparticles of poorly water-soluble drugs.
Azad, M; Bhakay, A; Bilgili, E; Dave, R, 2014
)
0.4
" This often leads to a high in vivo variability and bioavailability issues."( Site specific solubility improvement using solid dispersions of HPMC-AS/HPC SSL--mixtures.
Daniels, R; Meier, R; Wagner, KG; Zecevic, DE, 2014
)
0.4
" Milled GF with Povacoat® showed improved aqueous solubility and bioavailability compared with the other polymers."( Preparation and evaluation of high dispersion stable nanocrystal formulation of poorly water-soluble compounds by using povacoat.
Hashimoto, N; Horii, S; Nakada, Y; Seko, F; Takeuchi, H; Teramoto, K; Yuminoki, K, 2014
)
0.4
"The oral bioavailability of a poorly water-soluble drug is often inadequate for the desired therapeutic effect."( Controlled Dissolution of Griseofulvin Solid Dispersions from Electrosprayed Enteric Polymer Micromatrix Particles: Physicochemical Characterization and in Vitro Evaluation.
Araújo, F; Correia, A; Kaasalainen, M; Murtomaa, M; Peurla, M; Roine, J; Salonen, J; Santos, HA, 2015
)
0.72
"For the solubility and bioavailability of poorly soluble active pharmaceutical ingredients (APIs) to be improved, the transformation of crystalline APIs to the amorphous state has often been shown to be advantageous."( Predicting the Solubility Advantage of Amorphous Pharmaceuticals: A Novel Thermodynamic Approach.
Ji, Y; Paus, R; Sadowski, G; Vahle, L, 2015
)
0.42
"The aim of this study is to assess pullulan as a novel steric stabilizer during the wet-stirred media milling (WSMM) of griseofulvin, a model poorly water-soluble drug, and as a film-former in the preparation of strip films via casting-drying the wet-milled drug suspensions for dissolution and bioavailability enhancement."( Preparation and characterization of fast dissolving pullulan films containing BCS class II drug nanoparticles for bioavailability enhancement.
Bilgili, E; Davé, RN; Krull, SM; Li, M; Ma, Z, 2016
)
0.64
" It is estimated that about 40% of drugs in the development pipeline and approximately 60% of the drugs coming directly from discovery suffer from poor aqueous solubility and slow dissolution, thereby reducing their bioavailability and efficacy and thus preventing their commercialization."( High-Throughput Raman Spectroscopy Screening of Excipients for the Stabilization of Amorphous Drugs.
Chen, X; Kalantar, TH; Kuo, TC; Ladika, M; Stoneburner, K, 2015
)
0.42
"Griseofulvin (GRF) is an important antifungal drug with low bioavailability and, for this reason, a topical formulation with a targeted action and minimal systemic effects, appears to be a preferable solution."( Ethosomes for enhanced skin delivery of griseofulvin.
Ascenso, A; Eleutério, C; Guerreiro, A; Marto, J; Severino, C; Simões, S; Vitor, C, 2016
)
2.14
" Hence, MMC shows promise as a general drug delivery vehicle for increasing the bioavailability of compounds with dissolution rate- or solubility-limited absorption."( Supersaturation of poorly soluble drugs induced by mesoporous magnesium carbonate.
Bergström, C; Strømme, M; Welch, K; Zardán Gómez de la Torre, T; Zhang, P, 2016
)
0.43
"Nanocomposite microparticles (NCMPs) have been used in various solid dosage forms with the goal of enhancing the dissolution rate and bioavailability of poorly water-soluble drugs."( Quiescent and Agitated Redispersion as a Tool for Evaluating Dispersant Effectiveness in Dissolution Enhancement of Drug-Laden Nanocomposites.
Bhakay, A; Bilgili, E; Davé, RN, 2018
)
0.48
" The aim of this study was to improve the bioavailability and to evaluate and interpret the pharmacokinetic profiles after subcutaneous (s."( Nano- and microcrystals of griseofulvin subcutaneously administered to rats resulted in improved bioavailability and sustained release.
Rydberg, H; Sigfridsson, K; Strimfors, M, 2019
)
0.81
"Manufacturing poorly water-soluble active pharmaceutical ingredients (API) with sufficient bioavailability is a significant challenge in pharmaceutical research."( Preparation of submicron drug particles via spray drying from organic solvents.
Dobrowolski, A; Dräger-Gillessen, JF; Pieloth, D; Schaldach, G; Strob, R; Thommes, M; Wiggers, H, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" This study demonstrates successful preparation of fast supersaturating (190% within 20 min) HyNASDs, which renders nanoparticle formulations competitive to ASDs in bioavailability enhancement of poorly soluble drugs."( Hybrid nanocrystal-amorphous solid dispersions (HyNASDs) as alternative to ASDs for enhanced release of BCS Class II drugs.
Arevalo, F; Bilgili, E; Coelho, A; Rahman, M, 2019
)
0.51
"Amorphous solid dispersion (SD) technique has been used for improving the solubility and bioavailability of poorly water-soluble compounds."( Preparation and Characterization of Griseofulvin Solid Dispersions.
Chauhan, H; Sharma, P; Wani, RJ; Zhong, HA, 2020
)
0.83
"1-1 μm) has been identified by the pharmaceutical industry as a key technology to enhance the bioavailability of poorly water-soluble drugs."( Melt milling as manufacturing method for solid crystalline suspensions.
da Igreja, P; Erve, A; Thommes, M, 2021
)
0.62
" In this study, a recently patented green biopolymer (Prosopis africana gum, PG) was compatibilized with microcrystalline cellulose (MCC), a conventional polysaccharide, via thermo-regulated coacervation to obtain PG-MCC (1:0, 1:1, 1:2, 2:1, and 0:1) rational blends and the nanoparticles developed with optimized (1:1) biocomposites (termed "prosopisylated cellulose") by combined homogenization-nanoprecipitation technique was engineered as a high circulating system for improved oral bioavailability of griseofulvin (GF), a model Biopharmaceutics Classification System (BCS) Class-II drug."( Biodegradable nanoparticles from prosopisylated cellulose as a platform for enhanced oral bioavailability of poorly water-soluble drugs.
Dias, ML; Kenechukwu, FC; Ricci-Júnior, E, 2021
)
0.78

Dosage Studied

The effect of the amount of emulsified corn oil ingested on the gastrointestinal absorption of griseofulvin in man was assessed after oral administration of 5, 10, 15, or 30 gm doses of a corn oil (40% w/w)-in-water emulsion dosage form. PK profiling and in vivo phototoxicity testing demonstrated that a highly concentrated griseafulvin might cause phototoxic skin reactions in rats. While griseefulvin was effective to cause > 50% growth inhibition only at higher dosage of 400 ppm.

ExcerptRelevanceReference
" These results suggest that the stomach-emptying-controlled rabbit is useful for evaluating oral dosage forms for human use and that dose level selection is important in the bioavailability study of a barely water-soluble drug."( Use of rabbits for GI drug absorption studies: relationship between dissolution rate and bioavailability of griseofulvin tablets.
Maeda, T; Noguchi, T; Takenaka, H; Yamahira, Y, 1979
)
0.47
"The reported interaction of griseofulvin with phenobarbital was studied in the rat following oral administration of different dosage forms."( Griseofulvin---phenobarbital interaction: a formulation-dependent phenomenon.
Axelson, JE; Jamali, F, 1978
)
2
" The dosage was 5 mg/lb, with a maximum of 1 gm/day in both cases."( Intermittent use of griseofulvin in tinea capitis.
Oskui, J, 1978
)
0.58
" All the drugs caused rapid retraction of the neurites, which was reversible in all cases but for sodium dodecyl sulphate, and showed a sigmoid dose-response relationship."( Reversal of morphological differentiation of mouse neuroblastoma cells by mitosis-inhibitors and anesthetics.
Edström, A; Erkell, LJ; Hansson, HA, 1975
)
0.25
"The effect of the amount of emulsified corn oil ingested on the gastrointestinal absorption of griseofulvin in man was assessed after oral administration of 5, 10, 15, or 30 gm doses of a corn oil (40% w/w)-in-water emulsion dosage form, each containing 250 mg of microsize griseofulvin."( Gastrointestinal absorption of griseofulvin from corn oil-in-water emulsions: effect of amount of corn oil ingested in man.
Bates, TR; Pieniaszek, HJ; Rasmussen, JE; Sequeira, JA, 1977
)
0.76
" The physicochemical and pharmacotoxicological properties, antifungal range, mechanisms of action, dosage and preparations of griseofulvin, amphotericin-B, natamycin, nystatin and pecilocin are discussed."( [Antimycotic antibiotics (author's transl)].
Hagens, FM; van Miert, AS; van Soeren, JH, 1976
)
0.46
"A GLC method for the assay of griseofulvin in bulk and dosage forms was subjected to a wide and rigorous collaborative study."( GLC analysis of griseofulvin: a collaborative study.
Margosis, M, 1975
)
0.89
" The four dosage forms were administered in a random crossover fashion to five fasting subjects, and drug absorption was assessed from urinary excretion data for the major metabolite of the antibiotic (6-desmethylgriseofulvin)."( Bioavailability of micronized griseofulvin from corn oil-in-water emulsion, aqueous suspension, and commercial tablet dosage forms in humans.
Bates, TR; Sequeria, JA, 1975
)
0.73
" In humans it was proved that griseofulvin did not cause any accumulation in the serum with a dosage of 500 mg/day."( The quantitative determination of griseofulvin by gas chromatography (ECD-GC).
Suenaga, Y; Yasukawa, N, 1975
)
0.82
"This investigation was designed to quantitate and compare in the rat the oral absorption characteristics of micronized griseofulvin from a corn oil-in-water emulsion dosage form containing suspended drug and a control aqueous suspension after single-dose (50 mg/kg) and multiple-dose (50 mg/kg every 12 hr for five doses) administrations."( Apparent absorption kinetics of micronized griseofulvin after its oral administration on single- and multiple-dose regimens to rats as a corn oil-in-water emulsion and aqueous suspension.
Bates, TR; Carrigan, PJ, 1975
)
0.73
" For planning optimal clinical dosage regimes, it is necessary to know the rate of terbinafine movement through the nail plate, the concentrations achieved, and the persistence in the nail plate after stopping treatment."( Pharmacokinetics of terbinafine in the nail.
Finlay, AY, 1992
)
0.28
" Treatment consists of griseofulvin in a dosage of 10 mg/kg/day."( [Permanent hair loss after Kerion Celsi].
Bonven, TF; Iversen, E; Kragballe, K, 1991
)
0.59
" after dosing using a spectrofluorometric method, and pharmacokinetic parameters (Cp max, t max, AUC 0 - greater than 32) were calculated."( The bioavailability of griseofulvin from microsized and ultramicrosized tablets in nonfasting volunteers.
Bijanzadeh, M; Eshghi, L; Khazainia, T; Khosravy, A; Mahmoudian, M; Salehian, P, 1990
)
0.59
" The elimination of this main metabolite after dosing with L is lower (0."( The in vitro liberation and the bioavailability of different brands of griseofulvin in plasma and urine in man.
Feller, K; Le Petit, G; Pachaly, C; Terhaag, B, 1985
)
0.5
" The concentration of unbound griseofulvin in these body fluids was identical throughout the entire dosage interval."( Human plasma and skin blister fluid levels of griseofulvin after its repeated administration.
Korting, HC; Mutschler, E; Schäfer-Korting, M, 1985
)
0.82
" The rabbits which were not given food after oral dosing with griseofulvin exhibited a lower Cmax than those which were fed immediately after dosing."( Bioavailability of griseofulvin plain tablets in stomach-emptying controlled rabbits and the correlation with bioavailability in humans.
Aoyagi, N; Ejima, A; Kaniwa, N; Ogata, H, 1984
)
0.84
"A system is described for measurement of relative inhibition factors (RIFs) for antifungal agents--that is, the area under a fixed portion of the antifungal dose-response curve, expressed as a percentage of the area under the dose-response curve for a theoretical noninhibitory substance."( Relative inhibition factors--a novel approach to the assessment of antifungal antibiotics in vitro.
Abbott, AB; Odds, FC, 1984
)
0.27
" The different intensities of food effect on the bioavailabilities from two dosage forms suggest that formulation factors should be considered for the evaluation of food effect."( Effect of food on the bioavailability of griseofulvin from microsize and PEG ultramicrosize (GRIS-PEG) plain tablets.
Aoyagi, N; Ejima, A; Kaniwa, N; Ogata, H, 1982
)
0.53
" The results showed that one 330 mg ultramicrosize tablet is bioequivalent to two 165 mg ultramicrosize griseofulvin tablets and that either ultramicrosize griseofulvin dosage regimen is bioequivalent to 500 mg of the microsize griseofulvin formulation."( Comparative bioavailability of a microsize and ultramicrosize griseofulvin formulation in man.
DiGiore, C; Gural, R; Lim, J; Lin, C; Symchowicz, S, 1982
)
0.72
"The relative bioavailability of ten marketed dosage forms of griseofulvin was evaluated in two separate crossover studies."( Bioavailability of microsize and ultramicrosize griseofulvin products in man.
Meyer, MC; Raghow, G; Rotenberg, K; Straughn, AB, 1980
)
0.76
" We applied the properties of liposomes to overcome the poor gastro-intestinal (GI) absorption of griseofulvin and compared results with the traditional dosage form."( The gastro-intestinal absorption of griseofulvin can be enhanced by encapsulation into liposomes.
Liu, KM; Sue, MS; Yu, HS, 1993
)
0.78
" The statistical analyses of the data showed that the dose-response curves for aneuploidy induction did not differ quantitatively or qualitatively between the two meiotic divisions."( Dose-response study and threshold estimation of griseofulvin-induced aneuploidy during female mouse meiosis I and II.
Bairnsfather, L; London, SN; Mailhes, JB; Marchetti, F; Nandy, I, 1996
)
0.55
" A sensitivity analysis assessing alternative dosing regimens and a rank order stability analysis investigating the effects of length of treatment, success rates, relapse rates, and drug acquisition costs on overall results were also conducted."( Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model.
Marchetti, A; McGhan, WF; Neugut, AI; Piech, CT; Smith, BT,
)
0.13
" DeMonS has been applied to (i) the griseofulvin data for estimating drug absorbed at different time intervals when the drug disposition model parameters were determined separately from intravenous data, (ii) veralipride double-peak phenomenon data to estimate simultaneously the percentage of cumulative veralipride absorbed and the veralipride disposition model parameters without reference intravenous data, (iii) a comparative bioequivalence study of gastrointestinal therapeutic system (GITS) pseudoephedrine HCI (PeHCI) controlled-release oral dosage forms when the drug disposition model parameters were not available, and (iv) estimation of both drug disposition model parameters and the absorption rate of drug from Testoderm (testosterone transdermal system) in the presence of endogenous testosterone production."( DeMonS--a new deconvolution method for estimating drug absorbed at different time intervals and/or drug disposition model parameters using a monotonic cubic spline.
Gupta, SK; Hwang, SS; Yu, Z, 1997
)
0.57
" Five cats treated at the highest dosage of itraconazole vomited or became anorectic."( Efficacy of oral administration of itraconazole to cats with dermatophytosis caused by Microsporum canis.
Mancianti, F; Pedonese, F; Zullino, C, 1998
)
0.3
" First, the purpose of the study, the comparator drugs and their dosage regimens were defined."( Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails. A US analysis.
Gupta, AK, 1998
)
0.3
" Additionally, data concerning time- and dose-response induction of ALDH1A3 after phenobarbital and griseofulvin treatment are presented."( Phenobarbital inducibility and differences in protein expression of an animal model.
Karamanakos, P; Marselos, M; Pappas, P; Stephanou, P; Vasiliou, V, 2001
)
0.53
" However, these high rates were believed to be due to the high dosage of this drug and the prolonged course of treatment."( A randomized, double-blind, parallel-group, duration-finding study of oral terbinafine and open-label, high-dose griseofulvin in children with tinea capitis due to Microsporum species.
Chouela, E; Gourmala, N; Horvath, A; Lipozencic, J; Orofino-Costa, R; Paul, C; Romero, G; Skerlev, M; Zaitz, VC, 2002
)
0.53
" Dosage depends on body weight."( Management of onychomycosis in children.
Iorizzo, M; Piraccini, BM; Tosti, A, 2003
)
0.32
" It is possible that even higher cure rates and a shorter duration of therapy may be achieved following further optimization of treatment regimens that use a higher daily dosage of terbinafine than is currently recommended."( The efficacy and safety of terbinafine in children.
Cooper, EA; Gupta, AK; Lynde, CW, 2003
)
0.32
" Attempts to use a reduced dosage schedule did not prove satisfactory."( Treatment of superficial fungous infections. Value and limitations of systemic administration of griseofulvin.
AYRES, S, 1961
)
0.46
" With the assistance of the World Health Organization, a field trial was carried out in Yugoslavia to determine the most suitable schedule of dosage with this drug for mass treatment and to ascertain what measures are necessary to reduce the reservoir of infection to a level where the disease ceases to be a public health problem."( A controlled field trial in Yugoslavia of the efficacy of griseofulvin in the mass treatment of tinea capitis.
GRIN, EI, 1962
)
0.48
"Prior administration of phenobarbitone to male and female rats dosed orally or intravenously with griseofulvin caused a fall in blood levels of the antibiotic."( AN EFFECT OF PHENOBARBITONE ON GRISEOFULVIN METABOLISM IN THE RAT.
BUSFIELD, D; CHILD, KJ; TOMICH, EG, 1964
)
0.75
" This system is quite useful to predict the oral absorption of poorly water-soluble drugs after administration as solid dosage forms."( In vitro system to evaluate oral absorption of poorly water-soluble drugs: simultaneous analysis on dissolution and permeation of drugs.
Kataoka, M; Masaoka, Y; Sakane, T; Sezaki, H; Yamashita, S; Yamazaki, Y, 2003
)
0.32
" Studies included in this meta-analysis required a standard accepted dosage regimen, treatment duration and follow-up period."( Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis.
Gupta, AK; Johnson, AM; Ryder, JE, 2004
)
0.32
" Therapeutic dosage of Griseofulvin had no deleterious effect upon semen quality in dogs, although this does not preclude potential embryotoxic and teratogenic effects."( Influence of Griseofulvin treatment on semen quality in the dog.
England, GC; Sheldon, IM; von Heimendahl, A, 2004
)
1
" While griseofulvin was effective to cause > 50% growth inhibition only at higher dosage of 400 ppm."( Invitro drug sensitivity of Trichophyton species against griseofulvin and ketoconazole.
Bajpai, R; Dodia, S; Singh, BG,
)
0.83
"recognition of a dissecting cellulitis-like pattern of tinea capitis will increase clinical suspicion and avoid inappropriate management of a recalcitrant "dissecting cellulitis" in favor of prompt antifungal therapy of appropriate dosage and duration for patients with this unusual variant of tinea capitis."( Tinea capitis mimicking dissecting cellulitis: a distinct variant.
Sheth, AP; Twersky, JM, 2005
)
0.33
"Oral dosage forms are the preferred means of delivering drugs for systemic absorption."( Fast-dissolving microparticles fail to show improved oral bioavailability.
Kellaway, IW; Murdan, S; Wong, SM, 2006
)
0.33
"Solid dispersion (SD) of indomethacin with crospovidone (CrosPVP) shows useful characteristics for preparation of dosage forms."( Effect of characteristics of compounds on maintenance of an amorphous state in solid dispersion with crospovidone.
Fujii, M; Kokudai, M; Kondoh, M; Noda, S; Okada, H; Shibata, Y; Watanabe, Y, 2007
)
0.34
"Understanding responses of the cellular system for a dosing molecule is one of the most important problems in pharmacogenomics."( Analysis of gene networks for drug target discovery and validation.
Imoto, S; Miyano, S; Savoie, CJ; Tamada, Y, 2007
)
0.34
" Thus, this system may provide a useful dosage form for oral water-insoluble drugs which have problems in their dissolution."( Improving the high variable bioavailability of griseofulvin by SEDDS.
Al-Tabakha, MM; Arida, AI; Hamoury, HA, 2007
)
0.6
"The potential of poly(ethylene oxide)-poly(propylene oxide) block copolymers Pluronic F127 (PF127) and Tetronic 304 (T304), 904 (T904) and 1307 (T1307) as components of solid self-(micro)emulsifying dosage forms, S(M)EDDS, was evaluated."( Pluronic and tetronic copolymers with polyglycolyzed oils as self-emulsifying drug delivery systems.
Alvarez-Lorenzo, C; Concheiro, A; Fernandez-Tarrio, M; Immesoete, K; Yañez, F, 2008
)
0.35
"The use of solid dispersions for oral dosage forms can increase the dissolution rate of poorly soluble drugs."( Anomalous properties of spray dried solid dispersions.
Al-Obaidi, H; Brocchini, S; Buckton, G, 2009
)
0.35
" PK profiling and in vivo phototoxicity testing demonstrated that a highly concentrated griseofulvin in the skin might cause phototoxic skin reactions in rats, whereas oral administration of griseofulvin in single dosing regimen (20mg/kg) resulted in 10(3)-fold less skin deposition than phototoxic skin concentration of griseofulvin."( In vitro/in vivo phototoxic risk assessments of griseofulvin based on photobiochemical and pharmacokinetic behaviors.
Onoue, S; Seto, Y; Yamada, S, 2009
)
0.83
"Development of oral dosage forms containing poorly water-soluble drugs is a major challenge in the pharmaceutical industry."( Coaxial electrospray formulations for improving oral absorption of a poorly water-soluble drug.
Kataoka, M; Kawakami, K; Masaoka, Y; Sakuma, S; Yamamoto, M; Yamashita, S; Zhang, S, 2011
)
0.37
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" However, varying dosage schedules, changes in epidemiology, and rising drug resistance are factors that hamper treatment in some cases."( Comparative evaluation of griseofulvin, terbinafine and fluconazole in the treatment of tinea capitis.
Arora, P; Grover, C; Manchanda, V, 2012
)
0.68
" Response rates to griseofulvin are similar to rates seen in the 1970s, but require higher dosing and conversion to crushed tablets in partial responders."( Treatment outcomes for tinea capitis in a skin of color population.
Alexis, A; Bhanusali, D; Coley, M; Silverberg, JI; Silverberg, NB, 2012
)
0.71
" Presently, griseofulvin is available only in conventional oral dosage forms that suffer from the issues of poor and highly variable bioavailability, numerous systemic side effects and long duration of treatment."( Preparation and evaluation of antifungal efficacy of griseofulvin loaded deformable membrane vesicles in optimized guinea pig model of Microsporum canis--dermatophytosis.
Aggarwal, N; Goindi, S, 2012
)
1.01
" In this work, we consider the dissolution testing of griseofulvin (GF) particles, a poorly water-soluble compound, incorporated into a strip-film dosage form."( Using USP I and USP IV for discriminating dissolution rates of nano- and microparticle-loaded pharmaceutical strip-films.
Bhakay, A; Bilgili, E; Davé, RN; Keyvan, G; Michniak-Kohn, B; Pandya, N; Sievens-Figueroa, L, 2012
)
0.63
" The method could be very useful for the quality control of GF and its impurities in bulk and formulated dosage forms."( Development and validation of a reversed phase liquid chromatographic method for analysis of griseofulvin and impurities.
Adams, E; Adegoke, AO; Kahsay, G; Van Schepdael, A, 2013
)
0.61
" These positive attributes can help development of smaller, high drug-loaded dosage forms having enhanced bioavailability and better patient compliance."( Redispersible fast dissolving nanocomposite microparticles of poorly water-soluble drugs.
Azad, M; Bhakay, A; Bilgili, E; Dave, R, 2014
)
0.4
"Nanocomposite microparticles (NCMPs) have been used in various solid dosage forms with the goal of enhancing the dissolution rate and bioavailability of poorly water-soluble drugs."( Quiescent and Agitated Redispersion as a Tool for Evaluating Dispersant Effectiveness in Dissolution Enhancement of Drug-Laden Nanocomposites.
Bhakay, A; Bilgili, E; Davé, RN, 2018
)
0.48
" Thus, multi-layer hydrophilic polymer aqueous slurry-cast thick films containing poorly water-soluble drug particles provide a convenient dosage form capable of zero-order drug release with release time modulated through number of layers."( Zero-order release of poorly water-soluble drug from polymeric films made via aqueous slurry casting.
Alfano, J; Davé, RN; Race, D; Zhang, L, 2018
)
0.48
"Current dosing regimens of reported drugs are effective and safe for use in tinea capitis in children."( Tinea capitis in children: a systematic review of management.
Friedlander, SF; Gupta, AK; Mays, RR; Piguet, V; Piraccini, BM; Shear, NH; Tosti, A; Versteeg, SG, 2018
)
0.48
"Polymer strip film is a promising dosage form for oral delivery of poorly water-soluble drugs."( Convective Drying Kinetics of Polymer Strip Films Loaded with a BCS Class II Drug.
Bilgili, E; Cetindag, E; Davé, RN; Forte, J; Naseri, AT, 2019
)
0.51
" A higher bioavailability can reduce both the applied dosage and the side effects for the patient."( Preparation of submicron drug particles via spray drying from organic solvents.
Dobrowolski, A; Dräger-Gillessen, JF; Pieloth, D; Schaldach, G; Strob, R; Thommes, M; Wiggers, H, 2019
)
0.51
"To allow for tailored dosing and overcome swallowing difficulties, compounded liquid medication is often required in pediatric patients."( Stability of Azathioprine, Clonidine Hydrochloride, Clopidogrel Bisulfate, Ethambutol Hydrochloride, Griseofulvin, Hydralazine Hydrochloride, Nitrofurantoin, and Thioguanine Oral Suspensions Compounded with SyrSpend SF pH4.
Anagnostou, K; Cunha, CN; da Silva, SL; Dijkers, E; Ferreira, AO; Polonini, H,
)
0.35
" In conclusion, we recommend to relate to scaly scalp in high-risk populations as Tinea capitis, and to treat with griseofulvin at a dosage of up to 50 mg/kg/day, starting from the first presentation to the pediatrician."( Tinea capitis in an immigrant pediatric community; a clinical signs-based treatment approach.
Azrad, M; Kassem, R; Nitzan, O; Peretz, A; Shemesh, Y, 2021
)
0.83
" Currently, GF is only available in traditional oral dosage forms and suffers from poor and highly variable bioavailability, hepatotoxicity, and long duration of treatment."( Preparation and Evaluation of a Microsponge Dermal Stratum Corneum Retention Drug Delivery System for Griseofulvin.
Guo, S; Ma, L; Piao, J; Piao, M, 2022
)
0.94
"For solid oral dosage forms drug solubility in intestinal fluid is an important parameter influencing product performance and bioavailability."( Fed intestinal solubility limits and distributions applied to the Developability classification system.
Halbert, GW; Khadra, I; Pyper, K; Silva, MI, 2023
)
0.91
" Briefly, PULL/GSF-HPβCD-IC NF can be a promising dosage formulation as a fast-disintegrating delivery system for antifungal oral administration owing to the improved physicochemical properties of GSF."( Fast-Disintegrating Nanofibrous Web of Pullulan/Griseofulvin-Cyclodextrin Inclusion Complexes.
Celebioglu, A; Durgun, E; Hsiung, E; Kilic, ME; Uyar, T, 2023
)
1.17
" Recently, we have designed a novel topical formulation for griseofulvin (Gf) drug, which is currently commercially available in oral dosage forms due to its limited skin permeation."( Cytotoxicity, Dermal Toxicity, and In Vivo Antifungal Effect of Griseofulvin-Loaded Vaterite Carriers Administered via Sonophoresis.
Bosak, IA; Bucharskaya, AB; Kozlova, AA; Lengert, EV; Makarkin, MA; Mylnikov, AM; Navolokin, NA; Saveleva, MS; Svenskaya, YI; Terentyuk, GS; Vasilyeva, NV; Verkhovskii, RA, 2023
)
1.39
"The over-crowded day care centres and dense living make refugee children more susceptible to TC than the general population, and griseofulvin dosage adjustment is necessary."( Improved effectiveness of an increased dose of griseofulvin for treating Tinea capitis among refugee children in Israel: A retrospective cohort study.
Barzilai, A; Baum, S; Kassem, R; Kempfner, A; Pavlotsky, F, 2023
)
1.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antibacterial agentA substance (or active part thereof) that kills or slows the growth of bacteria.
Penicillium metaboliteAny fungal metabolite produced during a metabolic reaction in Penicillium.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
1-benzofuransA member of the class of benzofurans consisting of a 1-benzofuran skeleton and its substituted derivatives thereof.
oxaspiro compoundA spiro compound in which at least one of the cyclic components is an oxygen heterocyle.
antibiotic antifungal drugAny antibiotic antifungal agent used to treat fungal infections in humans or animals.
benzofuran antifungal drugAny member of the class of benzofurans which has been used as an antifungal drug.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (73)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency25.78770.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency25.78770.025120.237639.8107AID886; AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency28.18380.177814.390939.8107AID2147
Chain A, CruzipainTrypanosoma cruziPotency31.62280.002014.677939.8107AID1476
pregnane X receptorRattus norvegicus (Norway rat)Potency44.66840.025127.9203501.1870AID651751
RAR-related orphan receptor gammaMus musculus (house mouse)Potency12.46330.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency27.76950.173734.304761.8120AID1346859
ATAD5 protein, partialHomo sapiens (human)Potency20.58780.004110.890331.5287AID504466
SMAD family member 3Homo sapiens (human)Potency27.76950.173734.304761.8120AID1346859
TDP1 proteinHomo sapiens (human)Potency19.25490.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency9.49970.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency19.88290.000221.22318,912.5098AID588516; AID743035; AID743042; AID743054; AID743063
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency38.36460.013326.981070.7614AID1346978
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency28.80160.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency7.94330.001318.074339.8107AID926; AID938
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency21.49160.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency13.83460.001022.650876.6163AID1224838; AID1224893
progesterone receptorHomo sapiens (human)Potency28.84710.000417.946075.1148AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency34.67130.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency12.38770.000214.376460.0339AID720691
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency11.31530.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency17.22270.000817.505159.3239AID1159527; AID1159531; AID588544
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency13.87770.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency61.11720.375827.485161.6524AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency23.75610.005428.02631,258.9301AID1346982; AID1346985; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency15.94980.000229.305416,493.5996AID588513; AID743069; AID743075; AID743078
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency18.65780.001024.504861.6448AID588534; AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency33.60610.001019.414170.9645AID588537; AID743094; AID743140; AID743191
caspase-3Homo sapiens (human)Potency38.36460.013326.981070.7614AID1346978
IDH1Homo sapiens (human)Potency29.09290.005210.865235.4813AID686970
aryl hydrocarbon receptorHomo sapiens (human)Potency25.77850.000723.06741,258.9301AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency25.35450.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency15.70180.001628.015177.1139AID1224843; AID1224895
activating transcription factor 6Homo sapiens (human)Potency0.00340.143427.612159.8106AID1159516
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency28.18380.10009.191631.6228AID1346983
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency31.62280.001815.663839.8107AID894
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency23.10930.00419.984825.9290AID504444
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency70.79460.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency22.90330.000323.4451159.6830AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency10.29800.000627.21521,122.0200AID651741; AID743202; AID743219
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency7.94330.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency7.94330.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency7.94330.15855.287912.5893AID540303
gemininHomo sapiens (human)Potency20.88360.004611.374133.4983AID624296; AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency28.69540.005612.367736.1254AID624032
survival motor neuron protein isoform dHomo sapiens (human)Potency14.12540.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency15.84890.031610.279239.8107AID884; AID885
DNA dC->dU-editing enzyme APOBEC-3G isoform 1Homo sapiens (human)Potency35.48130.058010.694926.6086AID602310
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Cellular tumor antigen p53Homo sapiens (human)Potency41.56760.002319.595674.0614AID651631; AID720552
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Nuclear receptor ROR-gammaHomo sapiens (human)Potency1.18830.026622.448266.8242AID651802
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency8.91250.009610.525035.4813AID1479145
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency26.80530.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency24.41700.011912.222168.7989AID651632
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 1 Homo sapiens (human)IC50 (µMol)7.30000.21005.553710.0000AID1442001
Heme oxygenase 1 Rattus norvegicus (Norway rat)IC50 (µMol)100.00001.10004.320010.0000AID1799166
Heme oxygenase 2Rattus norvegicus (Norway rat)IC50 (µMol)100.00001.10004.483310.0000AID1799166
Lanosterol 14-alpha demethylaseHomo sapiens (human)IC50 (µMol)50.00000.05001.43904.0000AID322753
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (185)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processSolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin transportSolute carrier family 22 member 1 Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientSolute carrier family 22 member 1 Homo sapiens (human)
organic cation transportSolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transportSolute carrier family 22 member 1 Homo sapiens (human)
putrescine transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transportSolute carrier family 22 member 1 Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine transportSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transportSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 1 Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 1 Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
monoatomic cation transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
acyl carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
steroid biosynthetic processLanosterol 14-alpha demethylaseHomo sapiens (human)
cholesterol biosynthetic processLanosterol 14-alpha demethylaseHomo sapiens (human)
sterol metabolic processLanosterol 14-alpha demethylaseHomo sapiens (human)
negative regulation of protein catabolic processLanosterol 14-alpha demethylaseHomo sapiens (human)
negative regulation of protein secretionLanosterol 14-alpha demethylaseHomo sapiens (human)
negative regulation of amyloid-beta clearanceLanosterol 14-alpha demethylaseHomo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (66)

Processvia Protein(s)Taxonomy
acetylcholine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
dopamine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
secondary active organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
iron ion bindingLanosterol 14-alpha demethylaseHomo sapiens (human)
sterol 14-demethylase activityLanosterol 14-alpha demethylaseHomo sapiens (human)
heme bindingLanosterol 14-alpha demethylaseHomo sapiens (human)
oxidoreductase activityLanosterol 14-alpha demethylaseHomo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenLanosterol 14-alpha demethylaseHomo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (34)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
membraneSolute carrier family 22 member 1 Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
lateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
presynapseSolute carrier family 22 member 1 Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneLanosterol 14-alpha demethylaseHomo sapiens (human)
membraneLanosterol 14-alpha demethylaseHomo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (499)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347081qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Confirmatory Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347087qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Confirmatory Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347088qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): Viability assay - Alamar blue signal for LCMV Confirmatory Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347084qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Confirmatory Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1463408Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability by cell titer 96 aqueous one solution cell proliferation assay2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Chemoselective fluorination and chemoinformatic analysis of griseofulvin: Natural vs fluorinated fungal metabolites.
AID1294989Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by celltiter Glo assay2016European journal of medicinal chemistry, Jun-30, Volume: 116Strategies for improving the solubility and metabolic stability of griseofulvin analogues.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1551783Antibacterial activity against Staphylococcus aureus2019European journal of medicinal chemistry, Jul-01, Volume: 173Antibacterial activity study of 1,2,4-triazole derivatives.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID745307Antibacterial activity against Clostridium tetani MTCC 449 assessed as growth inhibition after overnight incubation by NCCLS broth microdilution method2013European journal of medicinal chemistry, May, Volume: 63Synthesis and identification of β-aryloxyquinoline based diversely fluorine substituted N-aryl quinolone derivatives as a new class of antimicrobial, antituberculosis and antioxidant agents.
AID613615Antibacterial activity against 10'8 CFU/mL Aspergillus fumigatus MTCC 3008 by NCCLS M100-S12(M7) broth microdilution method2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis and identification of β-aryloxyquinolines and their pyrano[3,2-c]chromene derivatives as a new class of antimicrobial and antituberculosis agents.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID382634Antifungal activity against Aspergillus fumigatus at 35 degC after 48 hrs2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Antimicrobial studies of 2,4-dichloro-5-fluorophenyl containing oxadiazoles.
AID613610Antibacterial activity against 10'8 CFU/mL Clostridium tetani MTCC 449 by NCCLS M100-S12(M7) broth microdilution method2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis and identification of β-aryloxyquinolines and their pyrano[3,2-c]chromene derivatives as a new class of antimicrobial and antituberculosis agents.
AID481660Antifungal activity against Candida albicans ATCC 90028 after 24 hrs by broth microdilution assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and the selective antifungal activity of 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives.
AID594998Antifungal activity against Penicillium marneffei after 48 hrs by Halo zone test2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Thermal solvent-free synthesis of novel pyrazolyl chalcones and pyrazolines as potential antimicrobial agents.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID293705Antifungal activity against Candida albicans MUCC 29 after 48 hrs by tube dilution method2007European journal of medicinal chemistry, Jun, Volume: 42, Issue:6
Synthetic studies on novel benzimidazolopeptides with antimicrobial, cytotoxic and anthelmintic potential.
AID613616Antibacterial activity against 10'8 CFU/mL Candida albicans MTCC 227 by NCCLS M100-S12(M7) broth microdilution method2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis and identification of β-aryloxyquinolines and their pyrano[3,2-c]chromene derivatives as a new class of antimicrobial and antituberculosis agents.
AID1082845Fungitoxicity against Fusarium oxysporum assessed as inhibition of mycelia growth at 28 +/- 1 degC at 10 ug/mL for 96 hr by poisoned food technique2012Journal of agricultural and food chemistry, Jun-13, Volume: 60, Issue:23
Synthesis and fungicidal activity of novel 3-(substituted/unsubstituted phenylselenonyl)-1-ribosyl/deoxyribosyl-1H-1,2,4-triazole.
AID386832Antibacterial activity against Escherichia coli at 100 ug/mL after 48 hrs by cup-plate method2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Synthesis and biological activities of some new fluorinated coumarins and 1-aza coumarins.
AID386841Antifungal activity against Rhizoctonia bataticola at 100 ug/mL after 48 hrs by cup-plate method2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Synthesis and biological activities of some new fluorinated coumarins and 1-aza coumarins.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1463407Cytotoxicity against human Huh7.5.1 cells assessed as reduction in cell viability by cell titer 96 aqueous one solution cell proliferation assay2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Chemoselective fluorination and chemoinformatic analysis of griseofulvin: Natural vs fluorinated fungal metabolites.
AID464212Antifungal activity against Candida albicans MTCC 277 after 24 hrs by cup plate method2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis, in vitro antibacterial and antifungal evaluations of new alpha-hydroxyphosphonate and new alpha-acetoxyphosphonate derivatives of tetrazolo [1, 5-a] quinoline.
AID758269Antifungal activity against Candida albicans MTCC 227 assessed as growth inhibition by broth microdilution method2013European journal of medicinal chemistry, Jul, Volume: 65Design and synthesis of biquinolone-isoniazid hybrids as a new class of antitubercular and antimicrobial agents.
AID1126673Antifungal activity against Aspergillus fumigatus MTCC 3008 assessed as growth inhibition after 24 to 48 hrs by broth microdilution method2014European journal of medicinal chemistry, May-06, Volume: 78Synthesis, characterization and pharmacological screening of some novel 5-imidazopyrazole incorporated polyhydroquinoline derivatives.
AID757548Anticandida activity against Candida krusei clinical isolate assessed as growth inhibition after 24 hrs by broth microdilution method2013European journal of medicinal chemistry, Jul, Volume: 65Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents.
AID665131Antifungal activity against 4 strains of Candida parapsilosis after 24 hrs by EUCAST broth microdilution method2012European journal of medicinal chemistry, Jul, Volume: 53Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID386840Antifungal activity against Aspergillus niger at 25 ug/mL after 48 hrs by cup-plate method2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Synthesis and biological activities of some new fluorinated coumarins and 1-aza coumarins.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1156892Antimicrobial activity against Aspergillus clavatus MTCC 1323 after 24 hrs by NCCLS M7-A5 method2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis and biological evaluation of novel N-aryl maleimide derivatives clubbed with α-hydroxyphosphonates.
AID416041Fungicidal activity against tebuconazole-adapted wild type Colletotrichum graminicola CgM2 assessed as inhibition of radial growth rate at 23 degC in darkness2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Treatment of a clinically relevant plant-pathogenic fungus with an agricultural azole causes cross-resistance to medical azoles and potentiates caspofungin efficacy.
AID666958Antibacterial activity against Bacillus subtilis MTCC 441 by broth microdilution method2012European journal of medicinal chemistry, Aug, Volume: 54New N-arylamino biquinoline derivatives: synthesis, antimicrobial, antituberculosis, and antimalarial evaluation.
AID19262Aqueous solubility2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Prediction of drug solubility from Monte Carlo simulations.
AID753514Antidermatophytic activity against Trichophyton mentagrophytes var. erinacei isolate after 7 days by broth microdilution method2013Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12
Evaluation of bioactivities of chlorokojic acid derivatives against dermatophytes couplet with cytotoxicity.
AID481663Antifungal activity against Candida tropicalis NRRL Y-12968 after 24 hrs by broth microdilution assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and the selective antifungal activity of 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives.
AID511053Antifungal activity against Aspergillus clavatus MTCC 1323 by broth microdilution method2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Pharmacological evaluation and characterizations of newly synthesized 1,2,4-triazoles.
AID1156888Antimicrobial activity against Escherichia coli ATCC 25922 after 24 hrs by NCCLS M7-A5 method2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis and biological evaluation of novel N-aryl maleimide derivatives clubbed with α-hydroxyphosphonates.
AID1224739Antimicrobial activity against Escherichia coli MTCC 443 by broth microdilution method2014European journal of medicinal chemistry, Aug-18, Volume: 83Ultrasound-assisted one-pot four-component synthesis of novel 2-amino-3-cyanopyridine derivatives bearing 5-imidazopyrazole scaffold and their biological broadcast.
AID623608Antifungal activity against 10'8 CFU/mL Aspergillus clavatus MTCC 1323 by broth microdilution method2011European journal of medicinal chemistry, Nov, Volume: 46, Issue:11
1,3-Dihydro-2H-indol-2-ones derivatives: design, synthesis, in vitro antibacterial, antifungal and antitubercular study.
AID293708Antifungal activity against Aspergillus niger MUCC 177 after 18 hrs by tube dilution method2007European journal of medicinal chemistry, Jun, Volume: 42, Issue:6
Synthetic studies on novel benzimidazolopeptides with antimicrobial, cytotoxic and anthelmintic potential.
AID1455949Antiviral activity against VSV pseudotyped HIV1 infected in SupT1 cells after 48 hrs by luciferase reporter gene assay2017Journal of natural products, 02-24, Volume: 80, Issue:2
Griseofulvin Derivative and Indole Alkaloids from Penicillium griseofulvum CPCC 400528.
AID1551784Antibacterial activity against Streptococcus pneumoniae2019European journal of medicinal chemistry, Jul-01, Volume: 173Antibacterial activity study of 1,2,4-triazole derivatives.
AID509483Antifungal activity against Penicillium citrinum2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Conventional and microwave assisted synthesis of some new N-[(4-oxo-2-substituted aryl -1, 3-thiazolidine)-acetamidyl]-5-nitroindazoles and its antimicrobial activity.
AID665133Antifungal activity against 4 strains of Candida glabrata after 24 hrs by EUCAST broth microdilution method2012European journal of medicinal chemistry, Jul, Volume: 53Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives.
AID1082843Fungitoxicity against Fusarium oxysporum assessed as inhibition of mycelia growth at 28 +/- 1 degC at 1000 ug/mL for 96 hr by poisoned food technique2012Journal of agricultural and food chemistry, Jun-13, Volume: 60, Issue:23
Synthesis and fungicidal activity of novel 3-(substituted/unsubstituted phenylselenonyl)-1-ribosyl/deoxyribosyl-1H-1,2,4-triazole.
AID1433841Antifungal activity against Candida albicans MTCC 227 after 24 to 48 hrs by broth microdilution method2017European journal of medicinal chemistry, Jan-27, Volume: 126Synthesis and biological screening of novel 2-morpholinoquinoline nucleus clubbed with 1,2,4-oxadiazole motifs.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1158015Antifungal activity against Aspergillus niger MTCC 282 by conventional broth microdilution method2014Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14
Studies on molecular properties prediction, antitubercular and antimicrobial activities of novel quinoline based pyrimidine motifs.
AID745302Antifungal activity against Aspergillus fumigatus MTCC 3008 assessed as growth inhibition after overnight incubation by NCCLS broth microdilution method2013European journal of medicinal chemistry, May, Volume: 63Synthesis and identification of β-aryloxyquinoline based diversely fluorine substituted N-aryl quinolone derivatives as a new class of antimicrobial, antituberculosis and antioxidant agents.
AID29421Partition coefficient (logP) (HPLC)2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
ElogPoct: a tool for lipophilicity determination in drug discovery.
AID1486827Antimicrobial activity against Streptococcus pyogenes MTCC 442 incubated for overnight by broth micro dilution method2017Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15
1,2,4-Triazole and 1,3,4-oxadiazole analogues: Synthesis, MO studies, in silico molecular docking studies, antimalarial as DHFR inhibitor and antimicrobial activities.
AID595000Antifungal activity against Aspergillus fumigatus after 48 hrs2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Thermal solvent-free synthesis of novel pyrazolyl chalcones and pyrazolines as potential antimicrobial agents.
AID595003Ratio of MIC to MFC for Candida albicans2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Thermal solvent-free synthesis of novel pyrazolyl chalcones and pyrazolines as potential antimicrobial agents.
AID293699Antifungal activity against Trichophyton mentagrophytes MUCC 665 after 48 hrs by disc diffusion method2007European journal of medicinal chemistry, Jun, Volume: 42, Issue:6
Synthetic studies on novel benzimidazolopeptides with antimicrobial, cytotoxic and anthelmintic potential.
AID1462722Antimicrobial activity against Escherichia coli MTCC 4432017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Benzothiazole analogues: Synthesis, characterization, MO calculations with PM6 and DFT, in silico studies and in vitro antimalarial as DHFR inhibitors and antimicrobial activities.
AID757547Anticandida activity against Candida parapsilosis clinical isolate assessed as growth inhibition after 24 hrs by broth microdilution method2013European journal of medicinal chemistry, Jul, Volume: 65Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents.
AID1156891Antimicrobial activity against Aspergillus niger MCIM 545 after 24 hrs by NCCLS M7-A5 method2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis and biological evaluation of novel N-aryl maleimide derivatives clubbed with α-hydroxyphosphonates.
AID382633Antifungal activity against Candida albicans at 35 degC after 48 hrs2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Antimicrobial studies of 2,4-dichloro-5-fluorophenyl containing oxadiazoles.
AID1272241Antifungal activity against Aspergillus clavatus by broth micro-dilution method2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Efficiently functionalized oxacalix[4]arenes: Synthesis, characterization and exploration of their biological profile as novel HDAC inhibitors.
AID1446902Cell cycle arrest in human U2OS cells assessed as accumulation at G2/M phase after 24 hrs by propidium iodide staining based flow cytometric method2017European journal of medicinal chemistry, Apr-21, Volume: 130Synthesis and formulation studies of griseofulvin analogues with improved solubility and metabolic stability.
AID511056Antifungal activity against Candida albicans MTCC 227 by broth microdilution method2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Pharmacological evaluation and characterizations of newly synthesized 1,2,4-triazoles.
AID399185Antifungal activity against Pyricularia grisea assessed as inhibition of germ-tube development by microdilution method2004Journal of natural products, Jan, Volume: 67, Issue:1
Antifungal 3-butylisocoumarins from Asteraceae-Anthemideae.
AID649239Antifungal activity against Trichophyton mentagrophytes IBT 2724 after 7 days by micro broth dilution method2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Disparate SAR data of griseofulvin analogues for the dermatophytes Trichophyton mentagrophytes, T. rubrum, and MDA-MB-231 cancer cells.
AID691707Antifungal activity against Saccharomyces cerevisiae MTCC 172 after 24 hrs by serial dilution method2012Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20
Synthesis of β-ionone derived chalcones as potent antimicrobial agents.
AID674912Antifungal activity against Aspergillus niger MTCC 2822012Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
Green synthesis and anti-infective activities of fluorinated pyrazoline derivatives.
AID1329366Antifungal activity against Microsporum canis CBS 113480 after 48 hrs by broth microdilution method2016Journal of natural products, 09-23, Volume: 79, Issue:9
Melokhanines A-J, Bioactive Monoterpenoid Indole Alkaloids with Diverse Skeletons from Melodinus khasianus.
AID753511Antidermatophytic activity against Epidermophyton floccosum RSKK 3027 after 7 days by broth microdilution method2013Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12
Evaluation of bioactivities of chlorokojic acid derivatives against dermatophytes couplet with cytotoxicity.
AID338691Antimicrobial activity against Staphylococcus aureus 209P IFO 12732 after 24 hrs by agar dilution streak method
AID386833Antibacterial activity against Escherichia coli at 50 ug/mL after 48 hrs by cup-plate method2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Synthesis and biological activities of some new fluorinated coumarins and 1-aza coumarins.
AID481662Antifungal activity against Candida utilis NRRL Y-900 after 24 hrs by broth microdilution assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and the selective antifungal activity of 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives.
AID386843Antifungal activity against Rhizoctonia bataticola at 25 ug/mL after 48 hrs by cup-plate method2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Synthesis and biological activities of some new fluorinated coumarins and 1-aza coumarins.
AID595004Ratio of MIC to MFC for Aspergillus fumigatus2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Thermal solvent-free synthesis of novel pyrazolyl chalcones and pyrazolines as potential antimicrobial agents.
AID382630Antifungal activity against Aspergillus fumigatus at 35 degC after 48 hrs by broth dilution method2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Antimicrobial studies of 2,4-dichloro-5-fluorophenyl containing oxadiazoles.
AID618673Antifungal activity against Candida albicans MTCC 183 at 10 ug/ml2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis, pharmacological evaluation and docking studies of coumarin derivatives.
AID1224736Antimicrobial activity against Streptococcus pneumoniae MTCC 1936 by broth microdilution method2014European journal of medicinal chemistry, Aug-18, Volume: 83Ultrasound-assisted one-pot four-component synthesis of novel 2-amino-3-cyanopyridine derivatives bearing 5-imidazopyrazole scaffold and their biological broadcast.
AID1595109Antifungal activity against Candida albicans assessed as reduction in fungal cell growth incubated for 24 and 72 hrs by cup plate method2019European journal of medicinal chemistry, May-15, Volume: 170Tetrazole hybrids and their antifungal activities.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID735214Antimicrobial activity against Aspergillus niger MTCC 282 assessed as growth inhibition measured after overnight incubation by broth dilution method2013European journal of medicinal chemistry, Apr, Volume: 62New 2-benzylsulfanyl-nicotinic acid based 1,3,4-oxadiazoles: their synthesis and biological evaluation.
AID665063Antifungal activity against Candida albicans MTCC 227 after 48 hrs by micro-broth dilution method2012Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11
An efficient one-pot synthesis, structure, antimicrobial and antioxidant investigations of some novel quinolyldibenzo[b,e][1,4]diazepinones.
AID613614Antibacterial activity against 10'8 CFU/mL Vibrio cholerae MTCC 3906 by NCCLS M100-S12(M7) broth microdilution method2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis and identification of β-aryloxyquinolines and their pyrano[3,2-c]chromene derivatives as a new class of antimicrobial and antituberculosis agents.
AID338698Antimicrobial activity against Trichophyton tonsurans var. sulfureum IFO 5945 after 7 days by agar dilution streak method
AID1595110Antifungal activity against Aspergillus flavus assessed as reduction in fungal cell growth incubated for 24 and 72 hrs by cup plate method2019European journal of medicinal chemistry, May-15, Volume: 170Tetrazole hybrids and their antifungal activities.
AID649241Cytotoxicity against human HeLa cells2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Disparate SAR data of griseofulvin analogues for the dermatophytes Trichophyton mentagrophytes, T. rubrum, and MDA-MB-231 cancer cells.
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID1486832Antifungal activity against Aspergillus clavatus MTCC 1323 incubated for overnight by broth micro dilution method2017Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15
1,2,4-Triazole and 1,3,4-oxadiazole analogues: Synthesis, MO studies, in silico molecular docking studies, antimalarial as DHFR inhibitor and antimicrobial activities.
AID1551786Antibacterial activity against Clostridium tetani2019European journal of medicinal chemistry, Jul-01, Volume: 173Antibacterial activity study of 1,2,4-triazole derivatives.
AID750278Antibacterial activity against Pseudomonas aeruginosa MTCC 441 assessed as growth inhibition by broth microdilution method2013European journal of medicinal chemistry, Jun, Volume: 64Synthetic tactics of new class of 4-aminothieno[2,3-d]pyrimidine-6-carbonitrile derivatives acting as antimicrobial agents.
AID386835Antibacterial activity against Bacillus cirrhosis at 100 ug/mL after 48 hrs by cup-plate method2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Synthesis and biological activities of some new fluorinated coumarins and 1-aza coumarins.
AID338693Antimicrobial activity against Micrococcus luteus IFO 12708 after 24 hrs by agar dilution streak method
AID589302Antifungal activity against Trichophyton mentagrophytes after 3 to 4 days by disc diffusion method2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
A facile, one-pot synthesis, characterization and antimicrobial activity of o-hydroxy anilide derivatives and 1-substituted-1,3-dicyclohexylurea analogs of long chain carboxylic acids.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID649242Antifungal activity against Trichophyton rubrum IBT 29284 after 7 days by micro broth dilution method2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Disparate SAR data of griseofulvin analogues for the dermatophytes Trichophyton mentagrophytes, T. rubrum, and MDA-MB-231 cancer cells.
AID311367Permeability coefficient in human skin2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
AID666965Antifungal activity against Candida albicans MTCC 227 by broth microdilution method2012European journal of medicinal chemistry, Aug, Volume: 54New N-arylamino biquinoline derivatives: synthesis, antimicrobial, antituberculosis, and antimalarial evaluation.
AID295720Antimicrobial activity against Candida albicans ATCC 14053 by broth dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
N- and S-alpha-l-arabinopyranosyl[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles. First synthesis and biological evaluation.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1636357Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1446893Thermodynamic solubility of the compound in phosphate buffered saline at pH 7.4 at 1 mg sonicated for 10 mins measured after 12 hrs by HPLC method2017European journal of medicinal chemistry, Apr-21, Volume: 130Synthesis and formulation studies of griseofulvin analogues with improved solubility and metabolic stability.
AID674913Antifungal activity against Aspergillus clavatus MTCC 13232012Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
Green synthesis and anti-infective activities of fluorinated pyrazoline derivatives.
AID589357Antifungal activity against Penicillium marneffei after 48 hrs by broth dilution technique2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
A facile, one-pot synthesis, characterization and antimicrobial activity of o-hydroxy anilide derivatives and 1-substituted-1,3-dicyclohexylurea analogs of long chain carboxylic acids.
AID293706Antifungal activity against Microsporum audouinii MUCC 545 after 48 hrs by tube dilution method2007European journal of medicinal chemistry, Jun, Volume: 42, Issue:6
Synthetic studies on novel benzimidazolopeptides with antimicrobial, cytotoxic and anthelmintic potential.
AID1290441Antibacterial activity against Bacillus subtilis MTCC 441 after 24 to 48 hrs by broth microdilution method2016European journal of medicinal chemistry, Apr-13, Volume: 112Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1462725Antimicrobial activity against Aspergillus clavatus MTCC 13232017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Benzothiazole analogues: Synthesis, characterization, MO calculations with PM6 and DFT, in silico studies and in vitro antimalarial as DHFR inhibitors and antimicrobial activities.
AID589358Antifungal activity against Trichophyton mentagrophytes after 48 hrs by broth dilution technique2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
A facile, one-pot synthesis, characterization and antimicrobial activity of o-hydroxy anilide derivatives and 1-substituted-1,3-dicyclohexylurea analogs of long chain carboxylic acids.
AID1730949Antifungal activity against Candida albicans MTCC 227 assessed as fungal growth inhibition2021Bioorganic & medicinal chemistry letters, 03-15, Volume: 36Structure based design, synthesis, and biological evaluation of imidazole derivatives targeting dihydropteroate synthase enzyme.
AID1433840Antibacterial activity against Escherichia coli MTCC 443 after 24 to 48 hrs by broth microdilution method2017European journal of medicinal chemistry, Jan-27, Volume: 126Synthesis and biological screening of novel 2-morpholinoquinoline nucleus clubbed with 1,2,4-oxadiazole motifs.
AID758272Antibacterial activity against Clostridium tetani MTCC 449 assessed as growth inhibition by broth microdilution method2013European journal of medicinal chemistry, Jul, Volume: 65Design and synthesis of biquinolone-isoniazid hybrids as a new class of antitubercular and antimicrobial agents.
AID1446888Stability in simulated gastric fluid at pH 1.2 assessed as compound remaining at 1 uM after 120 mins by LC-MS/MS method2017European journal of medicinal chemistry, Apr-21, Volume: 130Synthesis and formulation studies of griseofulvin analogues with improved solubility and metabolic stability.
AID386834Antibacterial activity against Escherichia coli at 25 ug/mL after 48 hrs by cup-plate method2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Synthesis and biological activities of some new fluorinated coumarins and 1-aza coumarins.
AID338700Antimicrobial activity against Epidermophyton floccosum IFO 9045 after 7 days by agar dilution streak method
AID623609Antifungal activity against 10'8 CFU/mL Aspergillus niger MTCC 282 by broth microdilution method2011European journal of medicinal chemistry, Nov, Volume: 46, Issue:11
1,3-Dihydro-2H-indol-2-ones derivatives: design, synthesis, in vitro antibacterial, antifungal and antitubercular study.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1446885Antiproliferative activity against human U2OS cells after 72 hrs by CellTiter-Glo luminescent assay2017European journal of medicinal chemistry, Apr-21, Volume: 130Synthesis and formulation studies of griseofulvin analogues with improved solubility and metabolic stability.
AID1156886Antimicrobial activity against Aspergillus clavatus MTCC 1323 at 100 ug/disc after 48 hrs by agar cup plate method2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis and biological evaluation of novel N-aryl maleimide derivatives clubbed with α-hydroxyphosphonates.
AID589303Antifungal activity against Candida albicans after 48 hrs by broth dilution technique2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
A facile, one-pot synthesis, characterization and antimicrobial activity of o-hydroxy anilide derivatives and 1-substituted-1,3-dicyclohexylurea analogs of long chain carboxylic acids.
AID1487472Antifungal activity against Trichoderma after 72 hrs by disk diffusion method2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
One-pot two-step facile synthesis of 2,3,4,5-tetra substituted dihydrooxazoles and their antimicrobial activity.
AID386837Antibacterial activity against Bacillus cirrhosis at 25 ug/mL after 48 hrs by cup-plate method2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Synthesis and biological activities of some new fluorinated coumarins and 1-aza coumarins.
AID730808Antifungal activity against Aspergillus fumigatus MTCC 3008 after 48 hrs by broth microdilution method2013Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
An efficient domino reaction in ionic liquid: synthesis and biological evaluation of some pyrano- and thiopyrano-fused heterocycles.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1433839Antibacterial activity against Vibrio cholerae MTCC 3906 after 24 to 48 hrs by broth microdilution method2017European journal of medicinal chemistry, Jan-27, Volume: 126Synthesis and biological screening of novel 2-morpholinoquinoline nucleus clubbed with 1,2,4-oxadiazole motifs.
AID618674Antifungal activity against Candida albicans MTCC 183 at 25 ug/ml2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis, pharmacological evaluation and docking studies of coumarin derivatives.
AID416040Fungicidal activity against tebuconazole-nonadapted wild type Colletotrichum graminicola CgM2 assessed as inhibition of radial growth rate at 23 degC in darkness2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Treatment of a clinically relevant plant-pathogenic fungus with an agricultural azole causes cross-resistance to medical azoles and potentiates caspofungin efficacy.
AID481442Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID338692Antimicrobial activity against Micrococcus roseus IFO 3764 after 24 hrs by agar dilution streak method
AID1224741Antimicrobial activity against Vibrio cholerae MTCC 3906 by broth microdilution method2014European journal of medicinal chemistry, Aug-18, Volume: 83Ultrasound-assisted one-pot four-component synthesis of novel 2-amino-3-cyanopyridine derivatives bearing 5-imidazopyrazole scaffold and their biological broadcast.
AID595001Antifungal activity against Trichophyton mentagrophytes after 48 hrs2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Thermal solvent-free synthesis of novel pyrazolyl chalcones and pyrazolines as potential antimicrobial agents.
AID1546127Antifungal activity against Candida albicans assessed as zone of inhibition at 50 ug/ml2019European journal of medicinal chemistry, Dec-15, Volume: 184Current scenario of tetrazole hybrids for antibacterial activity.
AID490975Antibacterial activity against Bacillus subtilis NCIM 2250 after 48 hrs by agar cup plate method2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and biological evaluation of new 2-chloro-3-((4-phenyl-1H-1,2,3-triazol-1-yl)methyl)quinoline derivatives via click chemistry approach.
AID1290442Antibacterial activity against Salmonella typhi MTCC 98 after 24 to 48 hrs by broth microdilution method2016European journal of medicinal chemistry, Apr-13, Volume: 112Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.
AID382631Antifungal activity against Penicillium marneffei at 35 degC after 48 hrs by broth dilution method2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Antimicrobial studies of 2,4-dichloro-5-fluorophenyl containing oxadiazoles.
AID481441Aqueous diffusivity at 37C2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID481668Antifungal activity against Candida glabrata clinical isolate 2 after 24 hrs by broth microdilution assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and the selective antifungal activity of 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1156887Antimicrobial activity against Bacillus subtilis NCIM 2250 after 24 hrs by NCCLS M7-A5 method2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis and biological evaluation of novel N-aryl maleimide derivatives clubbed with α-hydroxyphosphonates.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1329369Antifungal activity against Trichophyton terrestre after 48 hrs by broth microdilution method2016Journal of natural products, 09-23, Volume: 79, Issue:9
Melokhanines A-J, Bioactive Monoterpenoid Indole Alkaloids with Diverse Skeletons from Melodinus khasianus.
AID1446890Intrinsic clearance in Sprague-Dawley rat liver microsomes assessed per mg protein at 3 uM preincubated for 45 mins followed by NADPH addition by LC-MS/MS method2017European journal of medicinal chemistry, Apr-21, Volume: 130Synthesis and formulation studies of griseofulvin analogues with improved solubility and metabolic stability.
AID402109Antiinsectan activity against Carpophilus hemipterus assessed as reduction in feeding rate at 400 to 500 ppm relative to control1998Journal of natural products, Sep, Volume: 61, Issue:9
New p-terphenyl and polyketide metabolites from the sclerotia of Penicillium raistrickii.
AID481673Cytotoxicity against african pig LLC-PK11 up to 25 ug/ml after 48 hrs by neutral red assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and the selective antifungal activity of 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID649240Cytotoxicity against human SCC114 cells by phenotype-based spindle multipolarity assay2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Disparate SAR data of griseofulvin analogues for the dermatophytes Trichophyton mentagrophytes, T. rubrum, and MDA-MB-231 cancer cells.
AID1126672Antifungal activity against Candida albicans MTCC 227 assessed as growth inhibition after 24 to 48 hrs by broth microdilution method2014European journal of medicinal chemistry, May-06, Volume: 78Synthesis, characterization and pharmacological screening of some novel 5-imidazopyrazole incorporated polyhydroquinoline derivatives.
AID481667Antifungal activity against Candida albicans NRRL Y-12983 after 24 hrs by broth microdilution assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and the selective antifungal activity of 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives.
AID1546201Antifungal activity against Candida albicans MTCC 277 after 48 hrs by NCCLS protocol based method2019European journal of medicinal chemistry, Dec-15, Volume: 184Current scenario of tetrazole hybrids for antibacterial activity.
AID665130Antifungal activity against 3 strains of Candida krusei after 24 hrs by EUCAST broth microdilution method2012European journal of medicinal chemistry, Jul, Volume: 53Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives.
AID1183261Antimicrobial activity against Candida albicans MTCC 227 assessed as absence of visible growth after 24 to 48 hrs by broth micro dilution method2014European journal of medicinal chemistry, Sep-12, Volume: 84Design, synthesis and characterization of fluoro substituted novel pyrazolylpyrazolines scaffold and their pharmacological screening.
AID464389Antifungal activity against Candida albicans after 48 hrs by two fold dilution technique2010Bioorganic & medicinal chemistry letters, Mar-15, Volume: 20, Issue:6
Synthesis, characterization, and in vitro antimicrobial activities of 5-alkenyl/hydroxyalkenyl-2-phenylamine-1,3,4-oxadiazoles and thiadiazoles.
AID464210Antifungal activity against Candida albicans MTCC 277 after 48 hrs by agar cup plate method2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis, in vitro antibacterial and antifungal evaluations of new alpha-hydroxyphosphonate and new alpha-acetoxyphosphonate derivatives of tetrazolo [1, 5-a] quinoline.
AID613612Antibacterial activity against 10'8 CFU/mL Escherichia coli MTCC 443 by NCCLS M100-S12(M7) broth microdilution method2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis and identification of β-aryloxyquinolines and their pyrano[3,2-c]chromene derivatives as a new class of antimicrobial and antituberculosis agents.
AID1290439Antibacterial activity against Streptococcus pneumoniae MTCC 1936 after 24 to 48 hrs by broth microdilution method2016European journal of medicinal chemistry, Apr-13, Volume: 112Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.
AID398734Antifungal activity against Pleurotus ostreatus after 7 days by tube dilution method1995Journal of natural products, Sep, Volume: 58, Issue:9
New antifungal bithienylacetylenes from Blumea obliqua.
AID649243Cytotoxicity against human MDA-MB-231 cells assessed as cell viability after 48 hrs by MTT assay2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Disparate SAR data of griseofulvin analogues for the dermatophytes Trichophyton mentagrophytes, T. rubrum, and MDA-MB-231 cancer cells.
AID509478Antifungal activity against Fusarium oxysporum at 100 ug/mL2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Conventional and microwave assisted synthesis of some new N-[(4-oxo-2-substituted aryl -1, 3-thiazolidine)-acetamidyl]-5-nitroindazoles and its antimicrobial activity.
AID1433838Antibacterial activity against Salmonella typhi MTCC 98 after 24 to 48 hrs by broth microdilution method2017European journal of medicinal chemistry, Jan-27, Volume: 126Synthesis and biological screening of novel 2-morpholinoquinoline nucleus clubbed with 1,2,4-oxadiazole motifs.
AID536143Antimicrobial activity against Aspergillus niger MTCC 282 after 24 hrs by serial dilution method2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Design, synthesis and in vitro evaluation of antitubercular and antimicrobial activity of some novel pyranopyrimidines.
AID589304Antifungal activity against Aspergillus fumigatus after 48 hrs by broth dilution technique2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
A facile, one-pot synthesis, characterization and antimicrobial activity of o-hydroxy anilide derivatives and 1-substituted-1,3-dicyclohexylurea analogs of long chain carboxylic acids.
AID745303Antibacterial activity against Vibrio cholerae MTCC 3906 assessed as growth inhibition after overnight incubation by NCCLS broth microdilution method2013European journal of medicinal chemistry, May, Volume: 63Synthesis and identification of β-aryloxyquinoline based diversely fluorine substituted N-aryl quinolone derivatives as a new class of antimicrobial, antituberculosis and antioxidant agents.
AID665132Antifungal activity against 2 strains of Candida sake after 24 hrs by EUCAST broth microdilution method2012European journal of medicinal chemistry, Jul, Volume: 53Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives.
AID758274Antibacterial activity against Staphylococcus aureus MTCC 96 assessed as growth inhibition by broth microdilution method2013European journal of medicinal chemistry, Jul, Volume: 65Design and synthesis of biquinolone-isoniazid hybrids as a new class of antitubercular and antimicrobial agents.
AID37569Antifungal activity against Aspergillus niger MTCC 404 measured through zone of inhibition; 21-25 mm2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Amidine derived 1,3-diazabuta-1,3-dienes as potential antibacterial and antifungal agents.
AID469309Antifungal activity against Aspergillus fumigatus after 24 to 48 hrs by serial dilution technique2009European journal of medicinal chemistry, Dec, Volume: 44, Issue:12
Stereoselective synthesis and antimicrobial activity of benzofuran-based (1E)-1-(piperidin-1-yl)-N2-arylamidrazones.
AID1446889Intrinsic clearance in CD1 mouse liver microsomes assessed per mg protein at 3 uM preincubated for 45 mins followed by NADPH addition by LC-MS/MS method2017European journal of medicinal chemistry, Apr-21, Volume: 130Synthesis and formulation studies of griseofulvin analogues with improved solubility and metabolic stability.
AID509475Antifungal activity against Penicillium citrinum at 50 ug/mL2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Conventional and microwave assisted synthesis of some new N-[(4-oxo-2-substituted aryl -1, 3-thiazolidine)-acetamidyl]-5-nitroindazoles and its antimicrobial activity.
AID595002Antifungal activity against Penicillium marneffei after 48 hrs2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Thermal solvent-free synthesis of novel pyrazolyl chalcones and pyrazolines as potential antimicrobial agents.
AID382632Antifungal activity against Trichophyton mentagrophytes at 35 degC after 48 hrs by broth dilution method2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Antimicrobial studies of 2,4-dichloro-5-fluorophenyl containing oxadiazoles.
AID1294985Thermodynamic solubility in PBS buffer at 1 mg after 12 hrs by HPLC analysis2016European journal of medicinal chemistry, Jun-30, Volume: 116Strategies for improving the solubility and metabolic stability of griseofulvin analogues.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID753512Antidermatophytic activity against Microsporum gypseum isolate after 7 days by broth microdilution method2013Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12
Evaluation of bioactivities of chlorokojic acid derivatives against dermatophytes couplet with cytotoxicity.
AID1329368Antifungal activity against Trichophyton ajelloi E1501 after 48 hrs by broth microdilution method2016Journal of natural products, 09-23, Volume: 79, Issue:9
Melokhanines A-J, Bioactive Monoterpenoid Indole Alkaloids with Diverse Skeletons from Melodinus khasianus.
AID666963Antibacterial activity against Vibrio cholerae MTCC 3906 by broth microdilution method2012European journal of medicinal chemistry, Aug, Volume: 54New N-arylamino biquinoline derivatives: synthesis, antimicrobial, antituberculosis, and antimalarial evaluation.
AID464396Ratio of MFC to MIC for Penicillium marneffei2010Bioorganic & medicinal chemistry letters, Mar-15, Volume: 20, Issue:6
Synthesis, characterization, and in vitro antimicrobial activities of 5-alkenyl/hydroxyalkenyl-2-phenylamine-1,3,4-oxadiazoles and thiadiazoles.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1455950Antibacterial activity against Staphylococcus aureus after 18 hrs by broth microdilution method2017Journal of natural products, 02-24, Volume: 80, Issue:2
Griseofulvin Derivative and Indole Alkaloids from Penicillium griseofulvum CPCC 400528.
AID1294987Half life in rat liver microsomes by HPLC analysis in presence of NADPH2016European journal of medicinal chemistry, Jun-30, Volume: 116Strategies for improving the solubility and metabolic stability of griseofulvin analogues.
AID382635Antifungal activity against Penicillium marneffei at 35 degC after 48 hrs2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Antimicrobial studies of 2,4-dichloro-5-fluorophenyl containing oxadiazoles.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID481444Octanol-water partition coefficient, log P of the compound2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID623610Antifungal activity against 10'8 CFU/mL Candida albicans MTCC 227 by broth microdilution method2011European journal of medicinal chemistry, Nov, Volume: 46, Issue:11
1,3-Dihydro-2H-indol-2-ones derivatives: design, synthesis, in vitro antibacterial, antifungal and antitubercular study.
AID595005Ratio of MIC to MFC for Trichophyton mentagrophytes2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Thermal solvent-free synthesis of novel pyrazolyl chalcones and pyrazolines as potential antimicrobial agents.
AID490979Antibacterial activity against Bacillus subtilis NCIM 2250 after 24 to 72 hrs by cup plate method2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and biological evaluation of new 2-chloro-3-((4-phenyl-1H-1,2,3-triazol-1-yl)methyl)quinoline derivatives via click chemistry approach.
AID1329370Antifungal activity against Epidermophyton floccosum CBS 566.94 after 48 hrs by broth microdilution method2016Journal of natural products, 09-23, Volume: 79, Issue:9
Melokhanines A-J, Bioactive Monoterpenoid Indole Alkaloids with Diverse Skeletons from Melodinus khasianus.
AID594999Antifungal activity against Candida albicans after 48 hrs2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Thermal solvent-free synthesis of novel pyrazolyl chalcones and pyrazolines as potential antimicrobial agents.
AID481664Antifungal activity against Candida krusei NRRL Y-7179 after 24 hrs by broth microdilution assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and the selective antifungal activity of 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives.
AID481446Effective permeability across human jejunum2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1551782Antibacterial activity against Escherichia coli2019European journal of medicinal chemistry, Jul-01, Volume: 173Antibacterial activity study of 1,2,4-triazole derivatives.
AID481659Antifungal activity against Candida albicans clinical isolate after 24 hrs by broth microdilution assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and the selective antifungal activity of 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives.
AID338697Antimicrobial activity against Trichophyton mentagrophytes IFO 5809 after 7 days by agar dilution streak method
AID490980Antibacterial activity against Escherichia coli ATCC 25922 after 24 to 72 hrs by cup plate method2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and biological evaluation of new 2-chloro-3-((4-phenyl-1H-1,2,3-triazol-1-yl)methyl)quinoline derivatives via click chemistry approach.
AID464391Antifungal activity against Trichophyton mentagrophytes after 48 hrs by two fold dilution technique2010Bioorganic & medicinal chemistry letters, Mar-15, Volume: 20, Issue:6
Synthesis, characterization, and in vitro antimicrobial activities of 5-alkenyl/hydroxyalkenyl-2-phenylamine-1,3,4-oxadiazoles and thiadiazoles.
AID509476Antifungal activity against Penicillium citrinum at 100 ug/mL2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Conventional and microwave assisted synthesis of some new N-[(4-oxo-2-substituted aryl -1, 3-thiazolidine)-acetamidyl]-5-nitroindazoles and its antimicrobial activity.
AID1546125Antimicrobial activity against Staphylococcus aureus assessed as zone of inhibition at 50 ug/ml2019European journal of medicinal chemistry, Dec-15, Volume: 184Current scenario of tetrazole hybrids for antibacterial activity.
AID1463412Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability at 50 uM by cell titer 96 aqueous one solution cell proliferation assay2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Chemoselective fluorination and chemoinformatic analysis of griseofulvin: Natural vs fluorinated fungal metabolites.
AID1158014Antibacterial activity against Candida albicans MTCC 227 by conventional broth microdilution method2014Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14
Studies on molecular properties prediction, antitubercular and antimicrobial activities of novel quinoline based pyrimidine motifs.
AID666961Antibacterial activity against Escherichia coli MTCC 443 by broth microdilution method2012European journal of medicinal chemistry, Aug, Volume: 54New N-arylamino biquinoline derivatives: synthesis, antimicrobial, antituberculosis, and antimalarial evaluation.
AID753513Antidermatophytic activity against Microsporum gypseum NCPF 580 after 7 days by broth microdilution method2013Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12
Evaluation of bioactivities of chlorokojic acid derivatives against dermatophytes couplet with cytotoxicity.
AID1463414Antifungal activity against Microsporum gypseum at 25 ug/disc incubated for 5 days by agar disk diffusion method2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Chemoselective fluorination and chemoinformatic analysis of griseofulvin: Natural vs fluorinated fungal metabolites.
AID490650Antifungal activity against Candida albicans at 50 ug after 48 hrs by agar well diffusion assay2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Transition metal complexes of a new hexadentate macroacyclic N2O4-donor Schiff base: inhibitory activity against bacteria and fungi.
AID1546124Antimicrobial activity against Escherichia coli assessed as zone of inhibition at 50 ug/ml2019European journal of medicinal chemistry, Dec-15, Volume: 184Current scenario of tetrazole hybrids for antibacterial activity.
AID594997Antifungal activity against Trichophyton mentagrophytes after 48 hrs by Halo zone test2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Thermal solvent-free synthesis of novel pyrazolyl chalcones and pyrazolines as potential antimicrobial agents.
AID1455951Antibacterial activity against Escherichia coli after 18 hrs by broth microdilution method2017Journal of natural products, 02-24, Volume: 80, Issue:2
Griseofulvin Derivative and Indole Alkaloids from Penicillium griseofulvum CPCC 400528.
AID464388Antifungal activity against Trichophyton mentagrophytes after 48 hrs by disk diffusion method2010Bioorganic & medicinal chemistry letters, Mar-15, Volume: 20, Issue:6
Synthesis, characterization, and in vitro antimicrobial activities of 5-alkenyl/hydroxyalkenyl-2-phenylamine-1,3,4-oxadiazoles and thiadiazoles.
AID1486831Antifungal activity against Candida albicans MTCC 227 incubated for overnight by broth micro dilution method2017Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15
1,2,4-Triazole and 1,3,4-oxadiazole analogues: Synthesis, MO studies, in silico molecular docking studies, antimalarial as DHFR inhibitor and antimicrobial activities.
AID613609Antibacterial activity against 10'8 CFU/mL Bacillus subtilis MTCC 441 by NCCLS M100-S12(M7) broth microdilution method2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis and identification of β-aryloxyquinolines and their pyrano[3,2-c]chromene derivatives as a new class of antimicrobial and antituberculosis agents.
AID386839Antifungal activity against Aspergillus niger at 50 ug/mL after 48 hrs by cup-plate method2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Synthesis and biological activities of some new fluorinated coumarins and 1-aza coumarins.
AID511055Antifungal activity against Aspergillus niger MTCC 282 by broth microdilution method2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Pharmacological evaluation and characterizations of newly synthesized 1,2,4-triazoles.
AID1329373Antifungal activity against Microsporum gypseum CBS 118893 after 48 hrs by broth microdilution method2016Journal of natural products, 09-23, Volume: 79, Issue:9
Melokhanines A-J, Bioactive Monoterpenoid Indole Alkaloids with Diverse Skeletons from Melodinus khasianus.
AID77075Effect of oral administration (60 mg/kg) on course of expt. Ringworm infections in guinea pig by Trichophyton mentagrophytes1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Synthesis of (E)-1-(5-chlorothien-2-yl)-2-(1H-imidazol-1-yl)ethanone 2,6-dichlorophenylhydrazone hydrochloride, a novel, orally active antifungal agent.
AID467612Fraction unbound in human plasma2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID464211Antifungal activity against Aspergillus niger NCIM 545 after 48 hrs by agar cup plate method2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis, in vitro antibacterial and antifungal evaluations of new alpha-hydroxyphosphonate and new alpha-acetoxyphosphonate derivatives of tetrazolo [1, 5-a] quinoline.
AID386838Antifungal activity against Aspergillus niger at 100 ug/mL after 48 hrs by cup-plate method2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Synthesis and biological activities of some new fluorinated coumarins and 1-aza coumarins.
AID294714Antifungal activity against Aspergillus niger at 30 ug/ml by paper disc method2007European journal of medicinal chemistry, Jun, Volume: 42, Issue:6
Studies on synthesis and pharmacological activities of 3,6-disubstituted-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and their dihydro analogues.
AID464390Antifungal activity against Aspergillus fumigatus after 48 hrs by two fold dilution technique2010Bioorganic & medicinal chemistry letters, Mar-15, Volume: 20, Issue:6
Synthesis, characterization, and in vitro antimicrobial activities of 5-alkenyl/hydroxyalkenyl-2-phenylamine-1,3,4-oxadiazoles and thiadiazoles.
AID1294986Half life in mouse liver microsomes by HPLC analysis in presence of NADPH2016European journal of medicinal chemistry, Jun-30, Volume: 116Strategies for improving the solubility and metabolic stability of griseofulvin analogues.
AID437498Antifungal activity against Penicillium roqueforti NCIM 712 at 50 ug/ml by agar cup plate method2010European journal of medicinal chemistry, Jan, Volume: 45, Issue:1
Synthesis and antimicrobial activity of 7-(2-substituted phenylthiazolidinyl)-benzopyran-2-one derivatives.
AID1730951Antifungal activity against Aspergillus clavatus MTCC 1323 assessed as fungal growth inhibition2021Bioorganic & medicinal chemistry letters, 03-15, Volume: 36Structure based design, synthesis, and biological evaluation of imidazole derivatives targeting dihydropteroate synthase enzyme.
AID382626Antifungal activity against Aspergillus fumigatus at 37 degC after 3 to 4 days by agar dilution method2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Antimicrobial studies of 2,4-dichloro-5-fluorophenyl containing oxadiazoles.
AID386836Antibacterial activity against Bacillus cirrhosis at 50 ug/mL after 48 hrs by cup-plate method2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Synthesis and biological activities of some new fluorinated coumarins and 1-aza coumarins.
AID1082844Fungitoxicity against Fusarium oxysporum assessed as inhibition of mycelia growth at 28 +/- 1 degC at 100 ug/mL for 96 hr by poisoned food technique2012Journal of agricultural and food chemistry, Jun-13, Volume: 60, Issue:23
Synthesis and fungicidal activity of novel 3-(substituted/unsubstituted phenylselenonyl)-1-ribosyl/deoxyribosyl-1H-1,2,4-triazole.
AID1730948Antifungal activity against Aspergillus niger MTCC 282 assessed as fungal growth inhibition2021Bioorganic & medicinal chemistry letters, 03-15, Volume: 36Structure based design, synthesis, and biological evaluation of imidazole derivatives targeting dihydropteroate synthase enzyme.
AID1882194Antifungal activity against Helminthosporium oryzae assessed as inhibition of growth rate at 100 ug/ml by disc diffusion method relative to control2022European journal of medicinal chemistry, Feb-05, Volume: 229Natural and synthetic β-carboline as a privileged antifungal scaffolds.
AID1636356Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID382629Antifungal activity against Candida albicans at 35 degC after 48 hrs by broth dilution method2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Antimicrobial studies of 2,4-dichloro-5-fluorophenyl containing oxadiazoles.
AID1486830Antimicrobial activity against Pseudomonas aeruginosa MTCC 1688 incubated for overnight by broth micro dilution method2017Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15
1,2,4-Triazole and 1,3,4-oxadiazole analogues: Synthesis, MO studies, in silico molecular docking studies, antimalarial as DHFR inhibitor and antimicrobial activities.
AID1224743Antimicrobial activity against Aspergillus fumigatus MTCC 3008 by broth microdilution method2014European journal of medicinal chemistry, Aug-18, Volume: 83Ultrasound-assisted one-pot four-component synthesis of novel 2-amino-3-cyanopyridine derivatives bearing 5-imidazopyrazole scaffold and their biological broadcast.
AID1591945Cytotoxicity against mouse L5178Y cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Brominated Azaphilones from the Sponge-Associated Fungus
AID694216Antifungal activity against Candida albicans MTCC 227 after 48 hrs by serial broth dilution method2012Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22
Synthesis and characterization of some new quinoline based derivatives endowed with broad spectrum antimicrobial potency.
AID730807Antifungal activity against Candida albicans MTCC 227 after 48 hrs by broth microdilution method2013Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
An efficient domino reaction in ionic liquid: synthesis and biological evaluation of some pyrano- and thiopyrano-fused heterocycles.
AID481672Cytotoxicity against african green monkey Vero cells up to 25 ug/ml after 48 hrs by neutral red assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and the selective antifungal activity of 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives.
AID386842Antifungal activity against Rhizoctonia bataticola at 50 ug/mL after 48 hrs by cup-plate method2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Synthesis and biological activities of some new fluorinated coumarins and 1-aza coumarins.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID757550Anticandida activity against Candida glabrata clinical isolate assessed as growth inhibition after 24 hrs by broth microdilution method2013European journal of medicinal chemistry, Jul, Volume: 65Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents.
AID437499Antifungal activity against Aspergillus niger NCIM 813 at 50 ug/ml by agar cup plate method2010European journal of medicinal chemistry, Jan, Volume: 45, Issue:1
Synthesis and antimicrobial activity of 7-(2-substituted phenylthiazolidinyl)-benzopyran-2-one derivatives.
AID504051Antimicrobial activity against Candida albicans MTCC 227 by broth serial dilution technique2010Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18
Synthesis and antimicrobial activity of novel fluorine containing 4-(substituted-2-hydroxybenzoyl)-1H-pyrazoles and pyrazolyl benzo[d]oxazoles.
AID750275Antifungal activity against Candida albicans MTCC 227 assessed as growth inhibition by broth microdilution method2013European journal of medicinal chemistry, Jun, Volume: 64Synthetic tactics of new class of 4-aminothieno[2,3-d]pyrimidine-6-carbonitrile derivatives acting as antimicrobial agents.
AID1156889Antimicrobial activity against Candida albicans MTCC 277 after 24 hrs by NCCLS M7-A5 method2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis and biological evaluation of novel N-aryl maleimide derivatives clubbed with α-hydroxyphosphonates.
AID753510Antidermatophytic activity against Epidermophyton floccosum isolate after 7 days by broth microdilution method2013Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12
Evaluation of bioactivities of chlorokojic acid derivatives against dermatophytes couplet with cytotoxicity.
AID613611Antibacterial activity against 10'8 CFU/mL Streptococcus pneumoniae MTCC 1936 by NCCLS M100-S12(M7) broth microdilution method2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis and identification of β-aryloxyquinolines and their pyrano[3,2-c]chromene derivatives as a new class of antimicrobial and antituberculosis agents.
AID490977Antifungal activity against Candida albicans MTCC 277 after 48 hrs by agar cup plate method2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and biological evaluation of new 2-chloro-3-((4-phenyl-1H-1,2,3-triazol-1-yl)methyl)quinoline derivatives via click chemistry approach.
AID1224740Antimicrobial activity against Salmonella typhi MTCC 98 by broth microdilution method2014European journal of medicinal chemistry, Aug-18, Volume: 83Ultrasound-assisted one-pot four-component synthesis of novel 2-amino-3-cyanopyridine derivatives bearing 5-imidazopyrazole scaffold and their biological broadcast.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1082848Fungitoxicity against Penicillium citrinum assessed as inhibition of mycelia growth at 28 +/- 1 degC at 10 ug/mL for 96 hr by poisoned food technique2012Journal of agricultural and food chemistry, Jun-13, Volume: 60, Issue:23
Synthesis and fungicidal activity of novel 3-(substituted/unsubstituted phenylselenonyl)-1-ribosyl/deoxyribosyl-1H-1,2,4-triazole.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID464387Antifungal activity against Penicillium marneffei after 48 hrs by disk diffusion method2010Bioorganic & medicinal chemistry letters, Mar-15, Volume: 20, Issue:6
Synthesis, characterization, and in vitro antimicrobial activities of 5-alkenyl/hydroxyalkenyl-2-phenylamine-1,3,4-oxadiazoles and thiadiazoles.
AID649248Cytotoxicity against Chinese hamster V79 cells2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Disparate SAR data of griseofulvin analogues for the dermatophytes Trichophyton mentagrophytes, T. rubrum, and MDA-MB-231 cancer cells.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1433837Antibacterial activity against Bacillus subtilis MTCC 441 after 24 to 48 hrs by broth microdilution method2017European journal of medicinal chemistry, Jan-27, Volume: 126Synthesis and biological screening of novel 2-morpholinoquinoline nucleus clubbed with 1,2,4-oxadiazole motifs.
AID1546199Antimicrobial activity against Escherichia coli ATCC 25922 after 48 hrs by NCCLS protocol based method2019European journal of medicinal chemistry, Dec-15, Volume: 184Current scenario of tetrazole hybrids for antibacterial activity.
AID674911Antifungal activity against Candida albicans MTCC 2272012Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
Green synthesis and anti-infective activities of fluorinated pyrazoline derivatives.
AID399186Antifungal activity against Cladosporium herbarum assessed as inhibition zone in mycelial layer assessed per spot by TLC bioautography assay2004Journal of natural products, Jan, Volume: 67, Issue:1
Antifungal 3-butylisocoumarins from Asteraceae-Anthemideae.
AID1156890Antimicrobial activity against Candida tropicalis MTCC 184 after 24 hrs by NCCLS M7-A5 method2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis and biological evaluation of novel N-aryl maleimide derivatives clubbed with α-hydroxyphosphonates.
AID464205Antifungal activity against Aspergillus niger NCIM 545 after 24 hrs by cup plate method2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis, in vitro antibacterial and antifungal evaluations of new alpha-hydroxyphosphonate and new alpha-acetoxyphosphonate derivatives of tetrazolo [1, 5-a] quinoline.
AID618675Antifungal activity against Candida albicans MTCC 183 at 50 ug/ml2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis, pharmacological evaluation and docking studies of coumarin derivatives.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID662994Antifungal activity against Candida albicans MTCC 227 by macrobroth dilution assay2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
An improved microwave assisted one-pot synthesis, and biological investigations of some novel aryldiazenyl chromeno fused pyrrolidines.
AID1156885Antimicrobial activity against Aspergillus niger MCIM 545 at 100 ug/disc after 48 hrs by agar cup plate method2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis and biological evaluation of novel N-aryl maleimide derivatives clubbed with α-hydroxyphosphonates.
AID750276Antibacterial activity against Streptococcus pyogenes MTCC 442 assessed as growth inhibition by broth microdilution method2013European journal of medicinal chemistry, Jun, Volume: 64Synthetic tactics of new class of 4-aminothieno[2,3-d]pyrimidine-6-carbonitrile derivatives acting as antimicrobial agents.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID526306Antifungal activity against Aspergillus niger by agar plate disk diffusion method2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Bernthsen synthesis, antimicrobial activities and cytotoxicity of acridine derivatives.
AID758268Antifungal activity against Trichophyton rubrum MTCC 296 assessed as growth inhibition by broth microdilution method2013European journal of medicinal chemistry, Jul, Volume: 65Design and synthesis of biquinolone-isoniazid hybrids as a new class of antitubercular and antimicrobial agents.
AID750274Antifungal activity against Aspergillus niger MTCC 282 assessed as growth inhibition by broth microdilution method2013European journal of medicinal chemistry, Jun, Volume: 64Synthetic tactics of new class of 4-aminothieno[2,3-d]pyrimidine-6-carbonitrile derivatives acting as antimicrobial agents.
AID509484Antifungal activity against Fusarium oxysporum2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Conventional and microwave assisted synthesis of some new N-[(4-oxo-2-substituted aryl -1, 3-thiazolidine)-acetamidyl]-5-nitroindazoles and its antimicrobial activity.
AID469310Antifungal activity against Candida albicans after 24 to 48 hrs by serial dilution technique2009European journal of medicinal chemistry, Dec, Volume: 44, Issue:12
Stereoselective synthesis and antimicrobial activity of benzofuran-based (1E)-1-(piperidin-1-yl)-N2-arylamidrazones.
AID594996Antifungal activity against Aspergillus fumigatus after 48 hrs by Halo zone test2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Thermal solvent-free synthesis of novel pyrazolyl chalcones and pyrazolines as potential antimicrobial agents.
AID1446887Stability in mouse plasma assessed as compound remaining at 1 uM after 120 mins by LC-MS/MS method2017European journal of medicinal chemistry, Apr-21, Volume: 130Synthesis and formulation studies of griseofulvin analogues with improved solubility and metabolic stability.
AID1082846Fungitoxicity against Penicillium citrinum assessed as inhibition of mycelia growth at 28 +/- 1 degC at 1000 ug/mL for 96 hr by poisoned food technique2012Journal of agricultural and food chemistry, Jun-13, Volume: 60, Issue:23
Synthesis and fungicidal activity of novel 3-(substituted/unsubstituted phenylselenonyl)-1-ribosyl/deoxyribosyl-1H-1,2,4-triazole.
AID382636Antifungal activity against Trichophyton mentagrophytes at 35 degC after 48 hrs2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Antimicrobial studies of 2,4-dichloro-5-fluorophenyl containing oxadiazoles.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID80631Percent relaxation of isolated guinea pig trachea.1998Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5
New bronchodilators selected by molecular topology.
AID295719Antifungal activity against Syncephalastrum racemosum ATCC 18192 by broth dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
N- and S-alpha-l-arabinopyranosyl[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles. First synthesis and biological evaluation.
AID735213Antimicrobial activity against Aspergillus clavatus MTCC 1323 assessed as growth inhibition measured after overnight incubation by broth dilution method2013European journal of medicinal chemistry, Apr, Volume: 62New 2-benzylsulfanyl-nicotinic acid based 1,3,4-oxadiazoles: their synthesis and biological evaluation.
AID595006Ratio of MIC to MFC for Penicillium marneffei2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Thermal solvent-free synthesis of novel pyrazolyl chalcones and pyrazolines as potential antimicrobial agents.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1882193Antifungal activity against Aspergillus niger assessed as inhibition of growth rate at 100 ug/ml by disc diffusion method relative to control2022European journal of medicinal chemistry, Feb-05, Volume: 229Natural and synthetic β-carboline as a privileged antifungal scaffolds.
AID1462723Antimicrobial activity against Pseudomonas aeruginosa MTCC 16882017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Benzothiazole analogues: Synthesis, characterization, MO calculations with PM6 and DFT, in silico studies and in vitro antimalarial as DHFR inhibitors and antimicrobial activities.
AID1294993Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay2016European journal of medicinal chemistry, Jun-30, Volume: 116Strategies for improving the solubility and metabolic stability of griseofulvin analogues.
AID509482Antifungal activity against Aspergillus flavus2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Conventional and microwave assisted synthesis of some new N-[(4-oxo-2-substituted aryl -1, 3-thiazolidine)-acetamidyl]-5-nitroindazoles and its antimicrobial activity.
AID293698Antifungal activity against Microsporum audouinii MUCC 545 after 48 hrs by disc diffusion method2007European journal of medicinal chemistry, Jun, Volume: 42, Issue:6
Synthetic studies on novel benzimidazolopeptides with antimicrobial, cytotoxic and anthelmintic potential.
AID19427HPLC capacity factor (k)2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
ElogPoct: a tool for lipophilicity determination in drug discovery.
AID745306Antibacterial activity against Streptococcus pneumoniae MTCC 1936 assessed as growth inhibition after overnight incubation by NCCLS broth microdilution method2013European journal of medicinal chemistry, May, Volume: 63Synthesis and identification of β-aryloxyquinoline based diversely fluorine substituted N-aryl quinolone derivatives as a new class of antimicrobial, antituberculosis and antioxidant agents.
AID594995Antifungal activity against Candida albicans after 48 hrs by Halo zone test2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Thermal solvent-free synthesis of novel pyrazolyl chalcones and pyrazolines as potential antimicrobial agents.
AID1294988Cytotoxicity against human SCC114 cells assessed as reduction in cell viability after 24 hrs by MTT assay2016European journal of medicinal chemistry, Jun-30, Volume: 116Strategies for improving the solubility and metabolic stability of griseofulvin analogues.
AID295717Antifungal activity against Aspergillus fumigatus ATCC 96918 by broth dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
N- and S-alpha-l-arabinopyranosyl[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles. First synthesis and biological evaluation.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1158016Antifungal activity against Aspergillus clavatus MTCC 1323 by conventional broth microdilution method2014Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14
Studies on molecular properties prediction, antitubercular and antimicrobial activities of novel quinoline based pyrimidine motifs.
AID1294990Cytotoxicity against human U2OS cells assessed as reduction in cell viability after 72 hrs by celltiter Glo assay2016European journal of medicinal chemistry, Jun-30, Volume: 116Strategies for improving the solubility and metabolic stability of griseofulvin analogues.
AID1446892Fraction unbound in mouse plasma at 5 uM by LC-MS/MS method2017European journal of medicinal chemistry, Apr-21, Volume: 130Synthesis and formulation studies of griseofulvin analogues with improved solubility and metabolic stability.
AID1195236Antiproliferative activity against exponentially growing adherent human HCC1937 cells assessed as inhibition of cell proliferation after 72 hrs by luminescence detection based ATPlite assay2015Bioorganic & medicinal chemistry letters, , Volume: 25, Issue:10
Synthesis and activities towards resistant cancer cells of sulfone and sulfoxide griseofulvin derivatives.
AID589299Antifungal activity against Candida albicans after 3 to 4 days by disc diffusion method2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
A facile, one-pot synthesis, characterization and antimicrobial activity of o-hydroxy anilide derivatives and 1-substituted-1,3-dicyclohexylurea analogs of long chain carboxylic acids.
AID490976Antibacterial activity against Escherichia coli ATCC 25922 after 48 hrs by agar cup plate method2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and biological evaluation of new 2-chloro-3-((4-phenyl-1H-1,2,3-triazol-1-yl)methyl)quinoline derivatives via click chemistry approach.
AID622564Antifungal activity against Candida albicans MTCC 227 for 48 hrs by microdilution method2011Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20
Microwave assisted synthesis and antimicrobial evaluation of new fused pyran derivatives bearing 2-morpholinoquinoline nucleus.
AID464386Antifungal activity against Aspergillus fumigatus after 48 hrs by disk diffusion method2010Bioorganic & medicinal chemistry letters, Mar-15, Volume: 20, Issue:6
Synthesis, characterization, and in vitro antimicrobial activities of 5-alkenyl/hydroxyalkenyl-2-phenylamine-1,3,4-oxadiazoles and thiadiazoles.
AID295718Antifungal activity against Penicillium italicum ATCC 48114 by broth dilution method2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
N- and S-alpha-l-arabinopyranosyl[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles. First synthesis and biological evaluation.
AID1224742Antimicrobial activity against Candida albicans MTCC 227 by broth microdilution method2014European journal of medicinal chemistry, Aug-18, Volume: 83Ultrasound-assisted one-pot four-component synthesis of novel 2-amino-3-cyanopyridine derivatives bearing 5-imidazopyrazole scaffold and their biological broadcast.
AID481666Antifungal activity against Candida parapsilosis NRRL Y-12696 after 24 hrs by broth microdilution assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and the selective antifungal activity of 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives.
AID1546126Antifungal activity against Aspergillus niger assessed as zone of inhibition at 50 ug/ml2019European journal of medicinal chemistry, Dec-15, Volume: 184Current scenario of tetrazole hybrids for antibacterial activity.
AID745304Antibacterial activity against Salmonella typhi MTCC 98 assessed as growth inhibition after overnight incubation by NCCLS broth microdilution method2013European journal of medicinal chemistry, May, Volume: 63Synthesis and identification of β-aryloxyquinoline based diversely fluorine substituted N-aryl quinolone derivatives as a new class of antimicrobial, antituberculosis and antioxidant agents.
AID1329367Antifungal activity against Trichophyton mentagrophytes ATCC 4439 after 48 hrs by broth microdilution method2016Journal of natural products, 09-23, Volume: 79, Issue:9
Melokhanines A-J, Bioactive Monoterpenoid Indole Alkaloids with Diverse Skeletons from Melodinus khasianus.
AID758270Antibacterial activity against Pseudomonas aeruginosa MTCC 1688 assessed as growth inhibition by broth microdilution method2013European journal of medicinal chemistry, Jul, Volume: 65Design and synthesis of biquinolone-isoniazid hybrids as a new class of antitubercular and antimicrobial agents.
AID464392Antifungal activity against Penicillium marneffei after 48 hrs by two fold dilution technique2010Bioorganic & medicinal chemistry letters, Mar-15, Volume: 20, Issue:6
Synthesis, characterization, and in vitro antimicrobial activities of 5-alkenyl/hydroxyalkenyl-2-phenylamine-1,3,4-oxadiazoles and thiadiazoles.
AID1433836Antibacterial activity against Clostridium tetani MTCC 449 after 24 to 48 hrs by broth microdilution method2017European journal of medicinal chemistry, Jan-27, Volume: 126Synthesis and biological screening of novel 2-morpholinoquinoline nucleus clubbed with 1,2,4-oxadiazole motifs.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID589301Antifungal activity against Penicillium marneffei after 3 to 4 days by disc diffusion method2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
A facile, one-pot synthesis, characterization and antimicrobial activity of o-hydroxy anilide derivatives and 1-substituted-1,3-dicyclohexylurea analogs of long chain carboxylic acids.
AID481669Cytotoxicity against human SK-MEL cells up to 25 ug/ml after 48 hrs by neutral red assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and the selective antifungal activity of 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives.
AID1272239Antifungal activity against Candida albicans by broth micro-dilution method2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Efficiently functionalized oxacalix[4]arenes: Synthesis, characterization and exploration of their biological profile as novel HDAC inhibitors.
AID338699Antimicrobial activity against Microsporum gypseum IFO 8307 after 7 days by agar dilution streak method
AID490649Antifungal activity against Aspergillus niger at 50 ug after 48 hrs by agar well diffusion assay2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Transition metal complexes of a new hexadentate macroacyclic N2O4-donor Schiff base: inhibitory activity against bacteria and fungi.
AID1487473Antifungal activity against Pseudoperonospora cubensis after 48 to 72 hrs by disk diffusion method2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
One-pot two-step facile synthesis of 2,3,4,5-tetra substituted dihydrooxazoles and their antimicrobial activity.
AID1487475Antifungal activity against Phytophthora infestans after 48 to 72 hrs by disk diffusion method2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
One-pot two-step facile synthesis of 2,3,4,5-tetra substituted dihydrooxazoles and their antimicrobial activity.
AID294711Antifungal activity against Candida albicans at 30 ug/ml by paper disc method2007European journal of medicinal chemistry, Jun, Volume: 42, Issue:6
Studies on synthesis and pharmacological activities of 3,6-disubstituted-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and their dihydro analogues.
AID1224737Antimicrobial activity against Bacillus subtilis MTCC 441 by broth microdilution method2014European journal of medicinal chemistry, Aug-18, Volume: 83Ultrasound-assisted one-pot four-component synthesis of novel 2-amino-3-cyanopyridine derivatives bearing 5-imidazopyrazole scaffold and their biological broadcast.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID481671Cytotoxicity against human SKOV3 cells up to 25 ug/ml after 48 hrs by neutral red assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and the selective antifungal activity of 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives.
AID665129Antifungal activity against 10 strains of Candida albicans after 24 hrs by EUCAST broth microdilution method2012European journal of medicinal chemistry, Jul, Volume: 53Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives.
AID1195237Antiproliferative activity against exponentially growing adherent human HCC1937 cells assessed as inhibition of cell proliferation at 10 uM after 72 hrs by luminescence detection based ATPlite assay2015Bioorganic & medicinal chemistry letters, , Volume: 25, Issue:10
Synthesis and activities towards resistant cancer cells of sulfone and sulfoxide griseofulvin derivatives.
AID613613Antibacterial activity against 10'8 CFU/mL Salmonella typhi MTCC 98 by NCCLS M100-S12(M7) broth microdilution method2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis and identification of β-aryloxyquinolines and their pyrano[3,2-c]chromene derivatives as a new class of antimicrobial and antituberculosis agents.
AID1290445Antifungal activity against Candida albicans MTCC 227 after 24 to 48 hrs by broth microdilution method2016European journal of medicinal chemistry, Apr-13, Volume: 112Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.
AID1156883Antimicrobial activity against Candida albicans MTCC 277 at 100 ug/disc after 48 hrs by agar cup plate method2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis and biological evaluation of novel N-aryl maleimide derivatives clubbed with α-hydroxyphosphonates.
AID1636440Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID455986Permeability across human Caco-2 cells2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID694219Antifungal activity against Aspergillus clavatus MTCC 1323 after 48 hrs by serial broth dilution method2012Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22
Synthesis and characterization of some new quinoline based derivatives endowed with broad spectrum antimicrobial potency.
AID509477Antifungal activity against Fusarium oxysporum at 50 ug/mL2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Conventional and microwave assisted synthesis of some new N-[(4-oxo-2-substituted aryl -1, 3-thiazolidine)-acetamidyl]-5-nitroindazoles and its antimicrobial activity.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID354695Antimicrobial activity against Trichophyton mentagrophytes ATCC 9129 by agar dilution method1996Journal of natural products, Mar, Volume: 59, Issue:3
Phytogrowth-inhibitory and antifungal constituents of Helianthella quinquenervis.
AID665062Antifungal activity against Aspergillus fumigatus MTCC 3008 after 48 hrs by micro-broth dilution method2012Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11
An efficient one-pot synthesis, structure, antimicrobial and antioxidant investigations of some novel quinolyldibenzo[b,e][1,4]diazepinones.
AID691699Antifungal activity against Cryptococcus gastricus MTCC 1715 after 24 hrs by serial dilution method2012Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20
Synthesis of β-ionone derived chalcones as potent antimicrobial agents.
AID757546Anticandida activity against Candida sake clinical isolate assessed as growth inhibition after 24 hrs by broth microdilution method2013European journal of medicinal chemistry, Jul, Volume: 65Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents.
AID293700Antifungal activity against Aspergillus niger MUCC 177 after 48 hrs by disc diffusion method2007European journal of medicinal chemistry, Jun, Volume: 42, Issue:6
Synthetic studies on novel benzimidazolopeptides with antimicrobial, cytotoxic and anthelmintic potential.
AID633121Antifungal activity against Candida albicans2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
The synthesis of xanthones, xanthenediones, and spirobenzofurans: their antibacterial and antifungal activity.
AID666960Antibacterial activity against Streptococcus pneumoniae MTCC 1936 by broth microdilution method2012European journal of medicinal chemistry, Aug, Volume: 54New N-arylamino biquinoline derivatives: synthesis, antimicrobial, antituberculosis, and antimalarial evaluation.
AID1462724Antimicrobial activity against Candida albicans MTCC 2272017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Benzothiazole analogues: Synthesis, characterization, MO calculations with PM6 and DFT, in silico studies and in vitro antimalarial as DHFR inhibitors and antimicrobial activities.
AID622563Antifungal activity against Aspergillus fumigatus MTCC 3008 for 48 hrs by microdilution method2011Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20
Microwave assisted synthesis and antimicrobial evaluation of new fused pyran derivatives bearing 2-morpholinoquinoline nucleus.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1462720Antimicrobial activity against Staphylococcus aureus MTCC 962017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Benzothiazole analogues: Synthesis, characterization, MO calculations with PM6 and DFT, in silico studies and in vitro antimalarial as DHFR inhibitors and antimicrobial activities.
AID1446886Stability in rat plasma assessed as compound remaining at 1 uM after 120 mins by LC-MS/MS method2017European journal of medicinal chemistry, Apr-21, Volume: 130Synthesis and formulation studies of griseofulvin analogues with improved solubility and metabolic stability.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID27580Partition coefficient (logP)2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
ElogPoct: a tool for lipophilicity determination in drug discovery.
AID398733Antifungal activity against Epidermophyton floccosum after 7 days by tube dilution method1995Journal of natural products, Sep, Volume: 58, Issue:9
New antifungal bithienylacetylenes from Blumea obliqua.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1462721Antimicrobial activity against Streptococcus pyogenes MTCC 4422017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Benzothiazole analogues: Synthesis, characterization, MO calculations with PM6 and DFT, in silico studies and in vitro antimalarial as DHFR inhibitors and antimicrobial activities.
AID1551785Antibacterial activity against Bacillus subtilis2019European journal of medicinal chemistry, Jul-01, Volume: 173Antibacterial activity study of 1,2,4-triazole derivatives.
AID19424Partition coefficient (logD7.4)2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
AID662993Antifungal activity against Aspergillus fumigatus MTCC 3008 by macrobroth dilution assay2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
An improved microwave assisted one-pot synthesis, and biological investigations of some novel aryldiazenyl chromeno fused pyrrolidines.
AID753515Antidermatophytic activity against Trichophyton mentagrophytes var. erinacei NCPF 375 after 7 days by broth microdilution method2013Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12
Evaluation of bioactivities of chlorokojic acid derivatives against dermatophytes couplet with cytotoxicity.
AID666964Antifungal activity against Aspergillus fumigatus MTCC 3008 by broth microdilution method2012European journal of medicinal chemistry, Aug, Volume: 54New N-arylamino biquinoline derivatives: synthesis, antimicrobial, antituberculosis, and antimalarial evaluation.
AID666959Antibacterial activity against Clostridium tetani MTCC 449 by broth microdilution method2012European journal of medicinal chemistry, Aug, Volume: 54New N-arylamino biquinoline derivatives: synthesis, antimicrobial, antituberculosis, and antimalarial evaluation.
AID469314Antifungal activity against Candida albicans assessed as occurrence of cellular aggregation by microscopy2009European journal of medicinal chemistry, Dec, Volume: 44, Issue:12
Stereoselective synthesis and antimicrobial activity of benzofuran-based (1E)-1-(piperidin-1-yl)-N2-arylamidrazones.
AID293697Antifungal activity against Candida albicans MUCC 29 after 48 hrs by disc diffusion method2007European journal of medicinal chemistry, Jun, Volume: 42, Issue:6
Synthetic studies on novel benzimidazolopeptides with antimicrobial, cytotoxic and anthelmintic potential.
AID1433842Antifungal activity against Aspergillus fumigatus MTCC 3008 after 24 to 48 hrs by broth microdilution method2017European journal of medicinal chemistry, Jan-27, Volume: 126Synthesis and biological screening of novel 2-morpholinoquinoline nucleus clubbed with 1,2,4-oxadiazole motifs.
AID757549Anticandida activity against Candida tropicalis clinical isolate assessed as growth inhibition after 24 hrs by broth microdilution method2013European journal of medicinal chemistry, Jul, Volume: 65Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents.
AID1486828Antimicrobial activity against Staphylococcus aureus MTCC 96 incubated for overnight by broth micro dilution method2017Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15
1,2,4-Triazole and 1,3,4-oxadiazole analogues: Synthesis, MO studies, in silico molecular docking studies, antimalarial as DHFR inhibitor and antimicrobial activities.
AID509474Antifungal activity against Aspergillus flavus at 100 ug/mL2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Conventional and microwave assisted synthesis of some new N-[(4-oxo-2-substituted aryl -1, 3-thiazolidine)-acetamidyl]-5-nitroindazoles and its antimicrobial activity.
AID382628Antifungal activity against Trichophyton mentagrophytes at 37 degC after 3 to 4 days by agar dilution method2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Antimicrobial studies of 2,4-dichloro-5-fluorophenyl containing oxadiazoles.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1329357Antifungal activity against Microsporum ferrugineum CBS 457.80 after 48 hrs by broth microdilution method2016Journal of natural products, 09-23, Volume: 79, Issue:9
Melokhanines A-J, Bioactive Monoterpenoid Indole Alkaloids with Diverse Skeletons from Melodinus khasianus.
AID382625Antifungal activity against Candida albicans at 37 degC after 3 to 4 days by agar dilution method2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Antimicrobial studies of 2,4-dichloro-5-fluorophenyl containing oxadiazoles.
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID350566Inhibition of centrosomal clustering in human SCC114 cells expressing GFPalpha-tubulin assessed as mitotic cells with multipolar spindles by fluorescence microscopy2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
Synthesis and structure-activity relationship of griseofulvin analogues as inhibitors of centrosomal clustering in cancer cells.
AID1156884Antimicrobial activity against Candida tropicalis MTCC 184 at 100 ug/disc after 48 hrs by agar cup plate method2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis and biological evaluation of novel N-aryl maleimide derivatives clubbed with α-hydroxyphosphonates.
AID745301Antifungal activity against Candida albicans MTCC 227 assessed as growth inhibition after overnight incubation by NCCLS broth microdilution method2013European journal of medicinal chemistry, May, Volume: 63Synthesis and identification of β-aryloxyquinoline based diversely fluorine substituted N-aryl quinolone derivatives as a new class of antimicrobial, antituberculosis and antioxidant agents.
AID1487474Antifungal activity against Sphaerotheca fuliginea after 48 to 72 hrs by disk diffusion method2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
One-pot two-step facile synthesis of 2,3,4,5-tetra substituted dihydrooxazoles and their antimicrobial activity.
AID1546200Antifungal activity against Aspergillus niger NCIM 545 after 48 hrs by NCCLS protocol based method2019European journal of medicinal chemistry, Dec-15, Volume: 184Current scenario of tetrazole hybrids for antibacterial activity.
AID77236In vivo inhibition in guinea pig trichophytosis model1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Synthesis and structure-activity relationships of phenyl-substituted benzylamine antimycotics: a novel benzylbenzylamine antifungal agent for systemic treatment.
AID1487471Antifungal activity against Tilletia indica after 48 hrs by disk diffusion method2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
One-pot two-step facile synthesis of 2,3,4,5-tetra substituted dihydrooxazoles and their antimicrobial activity.
AID1156881Antimicrobial activity against Bacillus subtilis NCIM 2250 at 100 ug/disc after 24 hrs by agar cup plate method2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis and biological evaluation of novel N-aryl maleimide derivatives clubbed with α-hydroxyphosphonates.
AID758271Antibacterial activity against Salmonella typhi MTCC 98 assessed as growth inhibition by broth microdilution method2013European journal of medicinal chemistry, Jul, Volume: 65Design and synthesis of biquinolone-isoniazid hybrids as a new class of antitubercular and antimicrobial agents.
AID481439Absolute bioavailability in human2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1290443Antibacterial activity against Vibrio cholerae MTCC 3906 after 24 to 48 hrs by broth microdilution method2016European journal of medicinal chemistry, Apr-13, Volume: 112Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID750273Antifungal activity against Aspergillus clavatus MTCC 1323 assessed as growth inhibition by broth microdilution method2013European journal of medicinal chemistry, Jun, Volume: 64Synthetic tactics of new class of 4-aminothieno[2,3-d]pyrimidine-6-carbonitrile derivatives acting as antimicrobial agents.
AID691706Antifungal activity against Aspergillus niger MTCC 1344 after 24 hrs by serial dilution method2012Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20
Synthesis of β-ionone derived chalcones as potent antimicrobial agents.
AID1433835Antibacterial activity against Streptococcus pneumoniae MTCC 1936 after 24 to 48 hrs by broth microdilution method2017European journal of medicinal chemistry, Jan-27, Volume: 126Synthesis and biological screening of novel 2-morpholinoquinoline nucleus clubbed with 1,2,4-oxadiazole motifs.
AID666962Antibacterial activity against Salmonella typhi MTCC 98 by broth microdilution method2012European journal of medicinal chemistry, Aug, Volume: 54New N-arylamino biquinoline derivatives: synthesis, antimicrobial, antituberculosis, and antimalarial evaluation.
AID467613Volume of distribution at steady state in human2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID1290440Antibacterial activity against Clostridium tetani MTCC 449 after 24 to 48 hrs by broth microdilution method2016European journal of medicinal chemistry, Apr-13, Volume: 112Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.
AID12234881-Octanol-water distribution coefficient, log D of the compound at pH 7.42012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
AID1272240Antifungal activity against Aspergillus niger by broth micro-dilution method2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Efficiently functionalized oxacalix[4]arenes: Synthesis, characterization and exploration of their biological profile as novel HDAC inhibitors.
AID46906Antifungal activity against Candida albicans MTCC 183 measured through zone of inhibition; 21-25 mm2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Amidine derived 1,3-diazabuta-1,3-dienes as potential antibacterial and antifungal agents.
AID338696Antimicrobial activity against Trichophyton rubrum IFO 5808 after 7 days by agar dilution streak method
AID464385Antifungal activity against Candida albicans after 48 hrs by disk diffusion method2010Bioorganic & medicinal chemistry letters, Mar-15, Volume: 20, Issue:6
Synthesis, characterization, and in vitro antimicrobial activities of 5-alkenyl/hydroxyalkenyl-2-phenylamine-1,3,4-oxadiazoles and thiadiazoles.
AID402104Insecticidal activity against corn ear worm larvae at 400 to 500 ppm relative to control1998Journal of natural products, Sep, Volume: 61, Issue:9
New p-terphenyl and polyketide metabolites from the sclerotia of Penicillium raistrickii.
AID1463410Cytotoxicity against human OVCAR3 cells assessed as reduction in cell viability by cell titer 96 aqueous one solution cell proliferation assay2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Chemoselective fluorination and chemoinformatic analysis of griseofulvin: Natural vs fluorinated fungal metabolites.
AID757551Anticandida activity against Candida albicans clinical isolate assessed as growth inhibition after 24 hrs by broth microdilution method2013European journal of medicinal chemistry, Jul, Volume: 65Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents.
AID1486829Antimicrobial activity against Escherichia coli MTCC 443 incubated for overnight by broth micro dilution method2017Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15
1,2,4-Triazole and 1,3,4-oxadiazole analogues: Synthesis, MO studies, in silico molecular docking studies, antimalarial as DHFR inhibitor and antimicrobial activities.
AID750277Antibacterial activity against Staphylococcus aureus MTCC 96 assessed as growth inhibition by broth microdilution method2013European journal of medicinal chemistry, Jun, Volume: 64Synthetic tactics of new class of 4-aminothieno[2,3-d]pyrimidine-6-carbonitrile derivatives acting as antimicrobial agents.
AID382627Antifungal activity against Penicillium marneffei at 37 degC after 3 to 4 days by agar dilution method2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Antimicrobial studies of 2,4-dichloro-5-fluorophenyl containing oxadiazoles.
AID691708Antifungal activity against Candida albicans MTCC 3018 after 24 hrs by serial dilution method2012Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20
Synthesis of β-ionone derived chalcones as potent antimicrobial agents.
AID1595085Antifungal activity against Candida albicans MTCC 227 assessed as reduction in fungal cell growth incubated for 24 and 48 hrs by broth microdilution method2019European journal of medicinal chemistry, May-15, Volume: 170Tetrazole hybrids and their antifungal activities.
AID1442001Inhibition of human OCT1 expressed in HEK293 cells assessed as decrease in uptake of ASP+ after 2 mins by fluorescence assay2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1; SLC22A1).
AID1490957Cytotoxicity against human MCF7 cells after 3 days by sulforhodamine B assay2017Journal of natural products, 05-26, Volume: 80, Issue:5
Halogenated Compounds from Directed Fermentation of Penicillium concentricum, an Endophytic Fungus of the Liverwort Trichocolea tomentella.
AID1224738Antimicrobial activity against Clostridium tetani MTCC 449 by broth microdilution method2014European journal of medicinal chemistry, Aug-18, Volume: 83Ultrasound-assisted one-pot four-component synthesis of novel 2-amino-3-cyanopyridine derivatives bearing 5-imidazopyrazole scaffold and their biological broadcast.
AID1156882Antimicrobial activity against Escherichia coli ATCC 25922 at 100 ug/disc after 24 hrs by agar cup plate method2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis and biological evaluation of novel N-aryl maleimide derivatives clubbed with α-hydroxyphosphonates.
AID1490958Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay2017Journal of natural products, 05-26, Volume: 80, Issue:5
Halogenated Compounds from Directed Fermentation of Penicillium concentricum, an Endophytic Fungus of the Liverwort Trichocolea tomentella.
AID1183262Antimicrobial activity against Aspergillus fumigatus MTCC 3008 assessed as absence of visible growth after 24 to 48 hrs by broth micro dilution method2014European journal of medicinal chemistry, Sep-12, Volume: 84Design, synthesis and characterization of fluoro substituted novel pyrazolylpyrazolines scaffold and their pharmacological screening.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID758275Antibacterial activity against Bacillus subtilis MTCC 441 assessed as growth inhibition by broth microdilution method2013European journal of medicinal chemistry, Jul, Volume: 65Design and synthesis of biquinolone-isoniazid hybrids as a new class of antitubercular and antimicrobial agents.
AID509473Antifungal activity against Aspergillus flavus at 50 ug/mL2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Conventional and microwave assisted synthesis of some new N-[(4-oxo-2-substituted aryl -1, 3-thiazolidine)-acetamidyl]-5-nitroindazoles and its antimicrobial activity.
AID403740Antifungal activity against azole-resistant Candida albicans 99-7882005Journal of natural products, Aug, Volume: 68, Issue:8
Aspirochlorine class compounds from Aspergillus flavus inhibit azole-resistant Candida albicans.
AID481661Antifungal activity against Candida glabrata clinical isolate 1 after 24 hrs by broth microdilution assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and the selective antifungal activity of 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives.
AID745305Antibacterial activity against Escherichia coli MTCC 443 assessed as growth inhibition after overnight incubation by NCCLS broth microdilution method2013European journal of medicinal chemistry, May, Volume: 63Synthesis and identification of β-aryloxyquinoline based diversely fluorine substituted N-aryl quinolone derivatives as a new class of antimicrobial, antituberculosis and antioxidant agents.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID750279Antibacterial activity against Escherichia coli MTCC 443 assessed as growth inhibition by broth microdilution method2013European journal of medicinal chemistry, Jun, Volume: 64Synthetic tactics of new class of 4-aminothieno[2,3-d]pyrimidine-6-carbonitrile derivatives acting as antimicrobial agents.
AID403741Cytotoxicity against human CEM cells after 96 hrs2005Journal of natural products, Aug, Volume: 68, Issue:8
Aspirochlorine class compounds from Aspergillus flavus inhibit azole-resistant Candida albicans.
AID1591946Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2019Journal of natural products, 08-23, Volume: 82, Issue:8
Brominated Azaphilones from the Sponge-Associated Fungus
AID400612Antifungal activity against Trichophyton mentagrophytes ATCC 9129 by agar dilution method1996Journal of natural products, Feb, Volume: 59, Issue:2
Phytogrowth-inhibitory compounds from Malmea depressa.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID464394Ratio of MFC to MIC for Aspergillus fumigatus2010Bioorganic & medicinal chemistry letters, Mar-15, Volume: 20, Issue:6
Synthesis, characterization, and in vitro antimicrobial activities of 5-alkenyl/hydroxyalkenyl-2-phenylamine-1,3,4-oxadiazoles and thiadiazoles.
AID322753Inhibition of human CYP51 expressed in Topp 3 cells by lanosterol demethylase assay2007Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3
Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors.
AID745308Antibacterial activity against Bacillus subtilis MTCC 441 assessed as growth inhibition after overnight incubation by NCCLS broth microdilution method2013European journal of medicinal chemistry, May, Volume: 63Synthesis and identification of β-aryloxyquinoline based diversely fluorine substituted N-aryl quinolone derivatives as a new class of antimicrobial, antituberculosis and antioxidant agents.
AID1290446Antifungal activity against Aspergillus fumigatus MTCC 3008 after 24 to 48 hrs by broth microdilution method2016European journal of medicinal chemistry, Apr-13, Volume: 112Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.
AID1446891Fraction unbound in rat plasma at 5 uM by LC-MS/MS method2017European journal of medicinal chemistry, Apr-21, Volume: 130Synthesis and formulation studies of griseofulvin analogues with improved solubility and metabolic stability.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID589300Antifungal activity against Aspergillus fumigatus after 3 to 4 days by disc diffusion method2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
A facile, one-pot synthesis, characterization and antimicrobial activity of o-hydroxy anilide derivatives and 1-substituted-1,3-dicyclohexylurea analogs of long chain carboxylic acids.
AID464393Ratio of MFC to MIC for Candida albicans2010Bioorganic & medicinal chemistry letters, Mar-15, Volume: 20, Issue:6
Synthesis, characterization, and in vitro antimicrobial activities of 5-alkenyl/hydroxyalkenyl-2-phenylamine-1,3,4-oxadiazoles and thiadiazoles.
AID625277FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID665134Antifungal activity against 4 strains of Candida tropicalis after 24 hrs by EUCAST broth microdilution method2012European journal of medicinal chemistry, Jul, Volume: 53Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives.
AID1223490Apparent permeability across human differentiated Caco2 cells2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
AID338694Antimicrobial activity against Bacillus subtilis PCI 219 IFO 3513 after 24 hrs by agar dilution streak method
AID1546198Antimicrobial activity against Bacillus subtilis NCIM 2250 after 48 hrs by NCCLS protocol based method2019European journal of medicinal chemistry, Dec-15, Volume: 184Current scenario of tetrazole hybrids for antibacterial activity.
AID694217Antifungal activity against Aspergillus niger MTCC 282 after 48 hrs by serial broth dilution method2012Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22
Synthesis and characterization of some new quinoline based derivatives endowed with broad spectrum antimicrobial potency.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1195238Antiproliferative activity against exponentially growing adherent human SCC114 cells assessed as inhibition of cell proliferation after 72 hrs by luminescence detection based ATPlite assay2015Bioorganic & medicinal chemistry letters, , Volume: 25, Issue:10
Synthesis and activities towards resistant cancer cells of sulfone and sulfoxide griseofulvin derivatives.
AID1082847Fungitoxicity against Penicillium citrinum assessed as inhibition of mycelia growth at 28 +/- 1 degC at 100 ug/mL for 96 hr by poisoned food technique2012Journal of agricultural and food chemistry, Jun-13, Volume: 60, Issue:23
Synthesis and fungicidal activity of novel 3-(substituted/unsubstituted phenylselenonyl)-1-ribosyl/deoxyribosyl-1H-1,2,4-triazole.
AID464395Ratio of MFC to MIC for Trichophyton mentagrophytes2010Bioorganic & medicinal chemistry letters, Mar-15, Volume: 20, Issue:6
Synthesis, characterization, and in vitro antimicrobial activities of 5-alkenyl/hydroxyalkenyl-2-phenylamine-1,3,4-oxadiazoles and thiadiazoles.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1446884Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by CellTiter-Glo luminescent assay2017European journal of medicinal chemistry, Apr-21, Volume: 130Synthesis and formulation studies of griseofulvin analogues with improved solubility and metabolic stability.
AID691709Antifungal activity against Microsporum gypseum MTCC 4490 after 24 hrs by serial dilution method2012Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20
Synthesis of β-ionone derived chalcones as potent antimicrobial agents.
AID490978Antifungal activity against Aspergillus niger NCIM 545 after 48 hrs by agar cup plate method2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and biological evaluation of new 2-chloro-3-((4-phenyl-1H-1,2,3-triazol-1-yl)methyl)quinoline derivatives via click chemistry approach.
AID481665Antifungal activity against Candida zeylanoides NRRL Y-1774 after 24 hrs by broth microdilution assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and the selective antifungal activity of 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives.
AID1290444Antibacterial activity against Escherichia coli MTCC 443 after 24 to 48 hrs by broth microdilution method2016European journal of medicinal chemistry, Apr-13, Volume: 112Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.
AID338695Antimicrobial activity against Saccharomyces sake IFO 0305 after 7 days by agar dilution streak method
AID384955Intrinsic aqueous solubility at pH 10 by shake-flask method2008Journal of medicinal chemistry, May-22, Volume: 51, Issue:10
Molecular characteristics for solid-state limited solubility.
AID80624Percent relaxation using isolated guinea pig trachea.1998Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5
New bronchodilators selected by molecular topology.
AID293707Antifungal activity against Trichophyton mentagrophytes MUCC 665 after 48 hrs by tube dilution method2007European journal of medicinal chemistry, Jun, Volume: 42, Issue:6
Synthetic studies on novel benzimidazolopeptides with antimicrobial, cytotoxic and anthelmintic potential.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID735215Antimicrobial activity against Candida albicans MTCC 227 assessed as growth inhibition measured after overnight incubation by broth dilution method2013European journal of medicinal chemistry, Apr, Volume: 62New 2-benzylsulfanyl-nicotinic acid based 1,3,4-oxadiazoles: their synthesis and biological evaluation.
AID758273Antibacterial activity against Escherichia coli MTCC 443 assessed as growth inhibition by broth microdilution method2013European journal of medicinal chemistry, Jul, Volume: 65Design and synthesis of biquinolone-isoniazid hybrids as a new class of antitubercular and antimicrobial agents.
AID481670Cytotoxicity against human BT549 cells up to 25 ug/ml after 48 hrs by neutral red assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and the selective antifungal activity of 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives.
AID490981Antifungal activity against Candida albicans MTCC 277 after 24 to 72 hrs by cup plate method2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and biological evaluation of new 2-chloro-3-((4-phenyl-1H-1,2,3-triazol-1-yl)methyl)quinoline derivatives via click chemistry approach.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1799166In Vitro HO Activity Assay from Article 10.1124/jpet.106.102699: \\Inhibition of the enzymatic activity of heme oxygenases by azole-based antifungal drugs.\\2006The Journal of pharmacology and experimental therapeutics, Oct, Volume: 319, Issue:1
Inhibition of the enzymatic activity of heme oxygenases by azole-based antifungal drugs.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,042)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902037 (66.96)18.7374
1990's299 (9.83)18.2507
2000's284 (9.34)29.6817
2010's343 (11.28)24.3611
2020's79 (2.60)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 94.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index94.22 (24.57)
Research Supply Index8.13 (2.92)
Research Growth Index4.43 (4.65)
Search Engine Demand Index175.48 (26.88)
Search Engine Supply Index2.01 (0.95)

This Compound (94.22)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials115 (3.50%)5.53%
Reviews222 (6.75%)6.00%
Case Studies300 (9.12%)4.05%
Observational0 (0.00%)0.25%
Other2,652 (80.63%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Open Label, Randomized, Balanced, Three Treatment, Three Period, Three Sequence, Single Dose, Crossover Study to Evaluate the Bioequivalence of Test Griseofulvin Tablets, 500 mg Versus Reference Griseofulvin Tablets, 500 mg as Well as Dose Proportional [NCT04318535]Phase 136 participants (Actual)Interventional2020-01-13Completed
A Two-Way Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study Of Griseofulvin 125 mg/5 mL Suspension Versus Grifulvin V® 125 mg/5 mL Suspension In Normal, Healthy, Non-Smoking Male And Female Subjects [NCT00863863]Phase 140 participants (Actual)Interventional2006-01-31Completed
A Two-Way Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study Of Griseofulvin 125 mg/5 mL Suspension Versus Grifulvin V® 125 mg/5 mL Suspension In Normal, Healthy, Non-Smoking Male And Female Subjects [NCT00864071]Phase 150 participants (Actual)Interventional2005-11-30Completed
Efficacy and Safety of Terbinafine Compared to Griseofulvin in Children With Tinea Capitis [NCT00117767]Phase 3720 participants Interventional2004-06-30Completed
A Randomized, Double-Blinded, Placebo-Controlled Study Observing the Efficacy of Selenium Sulfide 1% Shampoo, Ketoconazole 2% Shampoo, and Ciclopirox 1% Shampoo as Adjunctive Treatments for Tinea Capitis in Children [NCT00127868]47 participants (Actual)Interventional2005-03-31Completed
A Two-way Cross-over, Placebo-controlled Interaction Trial in Two Parts (in Healthy Subjects), Studying Liraglutide's Potential Influence on the Absorption Pharmacokinetics of Lisinopril, Atorvastatin, Griseofulvin and Digoxin, and Liraglutide's Potential [NCT01518166]Phase 170 participants (Actual)Interventional2006-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT04318535 (12) [back to overview]Area Under Plasma Concentration-time Curve (AUC) From Zero Hours to Time of Last Quantifiable Concentration (AUC[0-t]) for Griseofulvin
NCT04318535 (12) [back to overview]AUC From Time Zero Extrapolated to Infinity (AUC[0-inf]) for Griseofulvin
NCT04318535 (12) [back to overview]Dose Proportionality of Griseofulvin Using AUC(0-t) Following a Single Dose
NCT04318535 (12) [back to overview]Dose Proportionality of Griseofulvin Using Cmax Following a Single Dose
NCT04318535 (12) [back to overview]Maximum Plasma Concentration (Cmax) for Griseofulvin
NCT04318535 (12) [back to overview]Number of Participants With Abnormal Urinalysis Dipstick Results
NCT04318535 (12) [back to overview]Number of Participants With Any Abnormality in Clinical Chemistry Parameter: Alanine Aminotransferase (ALT)
NCT04318535 (12) [back to overview]Number of Participants With Any Abnormality in Clinical Chemistry Parameters
NCT04318535 (12) [back to overview]Number of Participants With Any Abnormality in Hematology Parameters
NCT04318535 (12) [back to overview]Number of Participants With Any Abnormality in Vital Signs
NCT04318535 (12) [back to overview]Number of Participants With Any Serious Adverse Event (SAE) and Any Non-serious Adverse Event (Non-SAE)
NCT04318535 (12) [back to overview]Number of Participants With Positive Results in Serum Beta-human Chorionic Gonadotropin (Beta-hCG) Level (Females Participants)

Area Under Plasma Concentration-time Curve (AUC) From Zero Hours to Time of Last Quantifiable Concentration (AUC[0-t]) for Griseofulvin

Blood samples were collected to measure AUC(0-t) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. For Griseofulvin 250 mg (T2), dose-normalized AUC(0-t) (observed value multiplied by 2) is reported. Adjusted geometric mean and standard error have been presented for all treatments. Adjusted geometric mean is the antilog (exponential) of the least squares mean of the log-transformed data. Statistical analysis of pharmacokinetic parameters was done using mixed model for evaluation of bioquivalence. Point estimate and 90% confidence interval for the ratio of geometric least square mean of the test Griseofulvin 500 mg (T1) to the reference Griseofulvin 500 mg (R) were calculated for AUC(0-t) to assess bioequivalence. (NCT04318535)
Timeframe: Pre-dose (within 1 hour prior to dosing) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 8, 10, 12, 24, 48, 72 and 96 hours post-dose in each period

InterventionHours*nanogram per milliliter (Geometric Mean)
Griseofulvin 500 mg (T1)54993
Griseofulvin 250 mg (T2)66788
Griseofulvin 500 mg (R)53274

[back to top]

AUC From Time Zero Extrapolated to Infinity (AUC[0-inf]) for Griseofulvin

Blood samples were collected to measure AUC(0-inf) at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. For Griseofulvin 250 mg (T2), dose-normalized AUC(0-inf) (observed value multiplied by 2) is reported. Adjusted geometric mean and standard error have been presented for all treatments. Adjusted geometric mean is the antilog (exponential) of the least squares mean of the log-transformed data. Statistical analysis of pharmacokinetic parameters was done using mixed model for evaluation of bioquivalence. Point estimate and 90% confidence interval for the ratio of geometric least square mean of the test Griseofulvin 500 mg (T1) to the reference Griseofulvin 500 mg (R) were calculated for AUC(0-inf) to assess bioequivalence. (NCT04318535)
Timeframe: Pre-dose (within 1 hour prior to dosing) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 8, 10, 12, 24, 48, 72 and 96 hours post-dose in each period

InterventionHours*nanogram per milliliter (Geometric Mean)
Griseofulvin 500 mg (T1)56746
Griseofulvin 250 mg (T2)69564
Griseofulvin 500 mg (R)55100

[back to top]

Dose Proportionality of Griseofulvin Using AUC(0-t) Following a Single Dose

Blood samples were collected at indicated time-points for pharmacokinetic analysis. Pharmacokinetic parameters were measured using standard non-compartmental methods. Dose proportionality was assessed using mixed model. Slope and 90% confidence interval for the slope are presented. For Griseofulvin 250 mg (T2), dose-normalized (observed value multiplied by 2) AUC(0-t) was used during calculation of dose proportionality. (NCT04318535)
Timeframe: Pre-dose (within 1 hour prior to dosing) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 8, 10, 12, 24, 48, 72 and 96 hours post-dose in each period

InterventionSlope of log dose (Number)
Griseofulvin 250 mg to 500 mg1.214

[back to top]

Dose Proportionality of Griseofulvin Using Cmax Following a Single Dose

Blood samples were collected at indicated time-points for pharmacokinetic analysis. Pharmacokinetic parameters were measured using standard non-compartmental methods. Dose proportionality was assessed using mixed model. Slope and 90% confidence interval for the slope are presented. For Griseofulvin 250 mg (T2), dose-normalized (observed value multiplied by 2) Cmax was used during calculation of dose proportionality. (NCT04318535)
Timeframe: Pre-dose (within 1 hour prior to dosing) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 8, 10, 12, 24, 48, 72 and 96 hours post-dose in each period

InterventionSlope of log dose (Number)
Griseofulvin 250 mg to 500 mg1.290

[back to top]

Maximum Plasma Concentration (Cmax) for Griseofulvin

Blood samples were collected to measure Cmax at indicated time-points. Pharmacokinetic parameters were measured using standard non-compartmental methods. For Griseofulvin 250 mg (T2), dose-normalized Cmax (observed value multiplied by 2) is reported. Adjusted geometric mean and standard error have been presented for all treatments. Adjusted geometric mean is the antilog (exponential) of the least squares mean of the log-transformed data. Statistical analysis of pharmacokinetic parameters was done using mixed model for evaluation of bioquivalence. Point estimate and 90% confidence interval for the ratio of geometric least square mean of the test Griseofulvin 500 mg (T1) to the reference Griseofulvin 500 mg (R) were calculated for Cmax to assess bioequivalence. (NCT04318535)
Timeframe: Pre-dose (within 1 hour prior to dosing) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 8, 10, 12, 24, 48, 72 and 96 hours post-dose in each period

InterventionNanograms per milliliter (Geometric Mean)
Griseofulvin 500 mg (T1)2229
Griseofulvin 250 mg (T2)2877
Griseofulvin 500 mg (R)1927

[back to top]

Number of Participants With Abnormal Urinalysis Dipstick Results

Urine samples were collected to assess glucose, ketones, occult blood, protein, urobilinogen and bilirubin by dipstick method. The dipstick test gave results in a semi-quantitative manner, and results can be read as Negative, Trace, 1+, 2+ indicating proportional concentrations in the urine sample. Clinically acceptable range included 'negative' and 'trace' results. Number of participants with any abnormal urinalysis parameters are presented. (NCT04318535)
Timeframe: Up to Day 22

InterventionParticipants (Count of Participants)
Griseofulvin 500 mg (T1)0
Griseofulvin 250 mg (T2)0
Griseofulvin 500 mg (R)0

[back to top]

Number of Participants With Any Abnormality in Clinical Chemistry Parameter: Alanine Aminotransferase (ALT)

Blood samples were collected at indicated time points for assessment of clinical chemistry parameter. The clinically acceptable range for ALT included; Up to 7270 units per liter (U/L) (Male) and Up to 50 U/L (Female). Number of participants with any abnormality in ALT levels are presented. (NCT04318535)
Timeframe: Days -1, 7, 17 and 22

,,
InterventionParticipants (Count of Participants)
Day -1Day 7Day 17Day 22
Griseofulvin 250 mg (T2)0000
Griseofulvin 500 mg (R)0000
Griseofulvin 500 mg (T1)0000

[back to top]

Number of Participants With Any Abnormality in Clinical Chemistry Parameters

Blood samples were collected at indicated time points for assessment of clinical chemistry parameters. The clinically acceptable range included; blood urea: Up to 55 milligrams per deciliter (mg/dL), random blood glucose: 63-140 mg/dL, blood urea nitrogen: Up to 25 mg/dL, serum creatinine: 0.6-1.3 mg/dL (Male) and 0.4-1.0 mg/dL (Female), total serum bilirubin: 0.00-1.47 mg/dL, direct serum bilirubin: 0.0-0.3 mg/dL, indirect serum bilirubin: 0.0-1.5 mg/dL, aspartate aminotransferase (AST): Up to 70 units per liter (U/L) (Male) and Up to 50 U/L (Female). Number of participants with any abnormality in clinical chemistry parameters are presented. (NCT04318535)
Timeframe: Up to Day 22

,,
InterventionParticipants (Count of Participants)
Blood ureaRandom blood glucoseBlood urea nitrogenSerum creatinineTotal serum bilirubinDirect serum bilirubinIndirect serum bilirubinAST
Griseofulvin 250 mg (T2)00000000
Griseofulvin 500 mg (R)00000000
Griseofulvin 500 mg (T1)00000000

[back to top]

Number of Participants With Any Abnormality in Hematology Parameters

Blood samples were collected at indicated time points for assessment of hematology parameters. The clinically acceptable range included; hemoglobin: 12.3-18.0 grams per deciliter (g/dL) (for male) and 11.0-16.0 g/dL (for female), erythrocyte count: 4.0-7.1*10^12 cells per liter (for male) and 3.6-5.6*10^12 cells per liter (for female), hematocrit: 0.41-0.50 proportion of red blood cells in blood (Male) and 0.35-0.44 proportion of red blood cells in blood (Female), Mean Corpuscular Volume (MCV): 80-96 femtoliters, Mean Corpuscular Hemoglobin (MCH): 27.5-33.2 picogram , Mean Corpuscular Hemoglobin Concentration (MCHC): 33.4-35.5 g/dL, White Blood Cell (WBC) count: 3960-12100 cells per microliter, platelet count: 135-495*10^9 cells per liter, neutrophils: 36-88%, eosinophils: up to 14%, basophils: 0-2%, lymphocytes: 18-44%, monocytes: 2-10% of total cells. Number of participants with any abnormality in hematology parameters are presented. (NCT04318535)
Timeframe: Up to Day 22

,,
InterventionParticipants (Count of Participants)
HemoglobinErythrocyte countHematocritMCVMCHMCHCWBC countNeutrophils countEosinophils countBasophils countLymphocytes countMonocytes countPlatelet count
Griseofulvin 250 mg (T2)0000000000000
Griseofulvin 500 mg (R)0000001000000
Griseofulvin 500 mg (T1)0000000000000

[back to top]

Number of Participants With Any Abnormality in Vital Signs

Systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse rate, respiration rate and body temperature were measured in semi-supine position after 5 minutes rest. The clinically acceptable range included; SBP: 85 millimeters of mercury (mmHg) to 160 mmHg; DBP: 45 mmHg to 100 mmHg; pulse rate: 40 beats per minute to 110 beats per minute; respiration rate: 8 breaths per minute to 20 breaths per minute; body temperature: 35.5 degrees Celsius to 37.8 degrees Celsius. Number of participants with any abnormality in vital signs are presented. (NCT04318535)
Timeframe: Up to Day 22

,,
InterventionParticipants (Count of Participants)
SBPDBPPulse rateRespiration rateBody temperature
Griseofulvin 250 mg (T2)00000
Griseofulvin 500 mg (R)00000
Griseofulvin 500 mg (T1)00000

[back to top]

Number of Participants With Any Serious Adverse Event (SAE) and Any Non-serious Adverse Event (Non-SAE)

An adverse event was any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the medicinal product. An SAE was any untoward medical occurrence resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, congenital anomaly/birth defect or any other other important medical event that may jeopardize the participant or may require medical or surgical treatment to prevent one of the other outcomes listed before. (NCT04318535)
Timeframe: Up to Day 22

,,
InterventionParticipants (Count of Participants)
Any SAEAny non-SAE
Griseofulvin 250 mg (T2)00
Griseofulvin 500 mg (R)01
Griseofulvin 500 mg (T1)00

[back to top]

Number of Participants With Positive Results in Serum Beta-human Chorionic Gonadotropin (Beta-hCG) Level (Females Participants)

Blood samples were collected at indicated time points for assessment of serum beta-hCG (serum pregnancy test) for female participants. Number of participants with positive results in serum beta-hCG levels are presented. (NCT04318535)
Timeframe: Days -1, 7, 17 and 22

,,
InterventionParticipants (Count of Participants)
Day -1Day 7Day 17Day 22
Griseofulvin 250 mg (T2)0000
Griseofulvin 500 mg (R)0000
Griseofulvin 500 mg (T1)0000

[back to top]